review
rel
frequenc
caus
allogen
blood
transfusionrel
mortal
unit
state
today
present
possibl
strategi
reduc
transfusionrel
mortal
avoid
unnecessari
transfus
use
evidencebas
transfus
guidelin
reduc
potenti
fatal
infecti
well
noninfecti
transfus
complic
reduct
risk
transfusionrel
acut
lung
injuri
recipi
platelet
transfus
use
singledonor
platelet
collect
male
donor
femal
donor
without
histori
pregnanc
shown
white
blood
cell
wbc
antibodi
prevent
hemolyt
transfus
reaction
augment
patient
identif
procedur
addit
inform
technolog
well
prevent
addit
red
blood
cell
alloantibodi
format
patient
like
need
multipl
transfus
futur
avoid
pool
blood
product
pool
whole
bloodderiv
platelet
reduc
risk
transmiss
emerg
transfusiontransmit
infect
tti
residu
risk
known
tti
especi
transfusionassoci
sepsi
ta
wbc
reduct
cellular
blood
compon
administ
cardiac
surgeri
prevent
poorli
understood
increas
mortal
seen
cardiac
surgeri
patient
associ
receipt
nonwbcreduc
compar
wbcreduc
transfus
pathogen
reduct
platelet
plasma
compon
prevent
transfus
transmiss
emerg
potenti
fatal
tti
residu
risk
known
tti
especi
ta
elsevi
inc
right
reserv
nli
last
year
measur
implement
reduc
risk
lead
caus
transfusionrel
death
risk
transfusionrel
acut
lung
injuri
trali
transfusionassoci
sepsi
ta
togeth
abo
nonabo
hemolyt
transfus
reaction
htr
appear
common
caus
allogen
blood
transfus
abt
relat
mortal
seen
unit
state
today
although
etiolog
risk
known
year
measur
prevent
advoc
previous
march
novemb
respect
aabb
formerli
american
associ
blood
bank
recommend
blood
establish
limit
detect
bacteri
contamin
platelet
compon
well
collect
fresh
frozen
plasma
ffp
singledonor
platelet
sole
male
donor
femal
donor
without
histori
pregnanc
shown
white
blood
cell
wbc
antibodi
bacteri
contamin
blood
compon
result
introduct
low
concentr
skin
bacteria
time
phlebotomi
less
commonli
asymptomat
donor
bacteremia
rare
blood
process
variou
process
improv
start
introduc
around
platelet
red
blood
cell
rbc
respect
respons
fatal
ta
platelet
store
room
temperatureallow
bacteri
proliferationand
also
platelet
often
given
patient
suscept
bacteri
infect
neutropen
subject
also
often
impair
immun
system
accordingli
effort
reduc
risk
ta
hitherto
specif
target
platelet
compon
effort
reduc
risk
trali
target
specif
ffp
singledonor
platelet
depend
trali
defin
wbc
alloantibodi
identifi
donor
implic
trali
case
donor
antibodi
believ
attack
recipi
wbc
microcircul
lung
caus
noncardiogen
pulmonari
edema
donor
implic
trali
multipar
women
alloimmun
patern
wbc
alloantigen
pregnanc
blood
product
contain
larg
volum
plasma
individu
donor
thu
could
contain
larg
amount
wbc
antibodi
direct
cognat
wbc
antigen
particular
transfus
recipi
result
product
could
like
caus
trali
product
contain
small
volum
plasma
transfus
recipi
carri
correspond
wbc
alloantigen
possibl
led
recommend
ffp
singledonor
platelet
collect
sole
male
donor
femal
donor
without
histori
pregnanc
shown
wbc
antibodi
hemovigil
report
franc
unit
kingdom
provinc
quebec
canada
along
report
transfusionrel
death
us
food
drug
administr
fda
focus
attent
ta
trali
along
htr
major
contemporari
caus
abtrel
mortal
major
morbid
report
ensu
mandat
result
risk
ta
trali
least
partli
address
last
year
although
risk
htr
still
remain
directli
confront
well
attent
transfus
medicin
profession
remain
concentr
morbid
mortal
associ
transfusiontransmit
infect
tti
although
year
elaps
recognit
threat
human
immunodefici
viru
hiv
pose
blood
safeti
implement
donor
test
approxim
case
transfusionacquir
hiv
infect
estim
occur
unit
state
interv
recognit
introduct
test
longer
number
transfusionacquir
infect
correspondingli
higher
thu
million
case
hepat
c
viru
hcv
transmit
abt
even
result
fatal
cirrhosi
hepatocellular
carcinoma
longterm
survivor
transfus
recipi
surviv
long
enough
develop
complic
abtrel
death
could
still
ensu
mortal
tti
dwarf
concomit
mortal
trali
ta
htr
focus
blood
safeti
effort
toward
prevent
tti
result
past
decad
wit
impress
reduct
probabl
transmiss
hiv
hcv
abt
log
although
risk
tti
greatli
reduc
risk
new
poorli
understood
infecti
diseas
long
incub
period
transmit
abt
accumul
blood
donor
base
clinic
consequ
becom
appar
remain
fix
inevit
properti
transfus
medicin
thu
abt
still
transmit
lethal
infect
due
known
pathogen
especi
bacteria
even
novel
transfusiontransmit
potenti
transfusiontransmit
pathogen
continu
emerg
addit
death
caus
noninfecti
infecti
complic
abt
also
death
attribut
abt
observ
studi
random
control
trial
rct
pathophysiolog
mechan
yet
understand
particular
rct
compar
cardiac
surgeri
patient
random
receiv
nonwbcreduc
rbc
vs
rbc
wbc
remov
wbc
reduct
filter
attribut
increas
mortal
receipt
nonwbcreduc
compar
wbcreduc
abt
nonwbcreduc
compar
wbcreduc
abt
associ
defin
caus
death
rct
nevertheless
magnitud
absolut
risk
reduct
attribut
wbc
reduct
rct
van
de
water
et
al
impress
statist
signific
greater
mortal
vs
subject
receiv
nonwbcreduc
vs
wbcreduc
rbc
respect
although
overal
mortal
lower
unit
state
report
dutch
rct
potenti
wbcmediat
advers
abt
effect
could
account
larger
number
abtrel
death
current
establish
complic
abt
combin
observ
studi
compar
transfus
untransfus
patient
also
report
increas
mortal
associ
abt
per
se
independ
receipt
nonwbcreduc
vs
wbcreduc
rbc
transfus
requir
critic
care
tricc
rct
patient
alloc
receiv
rbc
transfus
base
restrict
vs
liber
transfus
criteria
demonstr
trend
p
toward
increas
mortal
well
increas
inhospit
mortal
p
associ
greater
exposur
abt
liber
transfus
arm
review
thu
present
estim
mortal
infecti
noninfecti
abt
complic
unit
state
today
advoc
adopt
specif
intervent
prevent
transfusionrel
death
particular
strategi
reduc
abtrel
mortal
assess
impact
upon
reduc
death
abt
data
transfus
complic
includ
death
transfus
complic
come
passiv
surveil
hemovigil
studi
activ
surveil
studi
well
rct
observ
studi
observ
studi
rct
evalu
consecut
transfus
patient
particular
set
part
research
protocol
andin
theorywould
expect
produc
reliabl
data
downsid
howev
usual
enrol
number
transfus
patient
much
small
document
incid
rare
transfus
complic
risk
death
abt
activ
surveil
studi
conduct
particular
hospit
sentinel
site
heighten
awar
special
arrang
made
detect
usual
specif
transfus
complic
passiv
surveil
system
reli
passiv
often
voluntari
report
advers
event
associ
abt
includ
abtrel
death
hemovigil
system
place
variou
countriesinclud
franc
unit
kingdom
european
countri
provinc
quebec
canada
coordin
hemovigil
system
exist
yet
unit
state
although
pilot
program
recent
introduc
moreov
report
identifi
transfusionrel
death
fda
requir
sinc
report
hemovigil
system
mandatori
franc
voluntari
use
unit
kingdom
recent
advers
event
includ
death
captur
system
depend
whether
particular
advers
event
caus
transfus
suspect
investig
possibl
andor
deem
transfus
relat
base
criteria
use
local
diagnosi
specif
transfus
complic
whether
abt
consid
possibl
caus
advers
event
death
vari
medic
nurs
staff
awar
transfus
complic
particular
clinic
set
well
local
cultur
resourc
logist
extent
investig
report
advers
event
along
design
channel
hemovigil
system
thu
hemovigil
system
tend
greatli
underestim
incid
abtrel
advers
tabl
contrast
incid
trali
report
passiv
surveil
sytem
activ
surveil
system
initi
particular
hosptial
observ
studi
critic
ill
patient
admit
intens
care
unit
icu
hemovigil
observ
studi
base
diagnos
trali
canadian
consensu
criteria
promulg
canadian
consensu
confer
wherea
studi
use
activ
surveil
system
conduct
earlierat
time
standard
definit
constel
find
qualifi
definit
possibl
trali
surveil
studi
encompass
transfus
patient
wherea
observ
studi
icu
patient
includ
critic
ill
patient
especi
import
trali
believ
result
interplay
patientand
transfusionrel
factor
may
thu
much
common
critic
ill
transfus
patient
critic
ill
patient
may
also
lower
threshold
trali
averag
transfus
recipi
sepsi
trauma
factor
may
repres
first
hit
hypothesi
trali
pathogenesi
critic
ill
patient
mani
case
acut
lung
injuri
ali
occur
presenc
one
sever
altern
caus
alican
misdiagnos
trali
mere
tempor
associ
abt
thu
differ
report
incid
trali
hemovigil
observ
studi
shown
tabl
due
partli
design
use
passiv
surveil
vs
observ
partli
patient
factor
andor
case
ali
misdiagnos
trali
multiplytransfus
patient
respiratori
distress
happen
manifest
within
hour
transfus
relev
patient
factor
notwithstand
howev
studi
use
criteria
diagnos
trali
tabl
underscor
extent
passiv
surveil
data
may
underestim
incid
seriou
abt
complic
number
death
relat
transfus
us
fda
transfus
deem
causal
contributori
role
unit
kingdom
shot
shown
column
death
secondari
septic
reaction
platelet
deem
caus
abt
unit
kingdom
case
includ
case
inappropri
transfus
febril
nonhemolyt
transfus
reaction
transfus
deem
contribut
patient
death
awar
transfus
complic
increas
resourc
expend
detect
transfus
complic
report
transfus
complic
hemovigil
system
increas
condit
satisfi
implement
bacteri
detect
platelet
john
hopkin
hospit
baltimor
md
year
ness
et
al
implement
system
prospect
monitor
wherebi
febril
transfus
reaction
platelet
assess
cultur
start
baselin
therapeut
platelet
dose
hospit
provid
singledonor
platelet
observ
thata
proport
therapeut
platelet
dose
provid
singledonor
platelet
oppos
platelet
pool
increas
risk
ta
declin
platelet
transfus
decreas
risk
could
extrapol
reduct
expect
risk
ta
per
platelet
pool
author
start
therapeut
platelet
dose
provid
singledonor
platelet
virtual
ident
risk
per
platelet
pool
per
platelet
pool
observ
first
year
quebec
hemovigil
program
reli
hospit
cultur
platelet
pool
implic
transfus
reaction
staf
transfus
offic
contrast
french
hemovigil
systemprob
comprehens
passiv
surveil
system
entail
mandatori
reportingobserv
risk
sepsi
secondari
platelet
transfusionif
pool
platelet
concentr
assumedof
per
platelet
pool
report
risk
far
lower
unit
kingdom
hemovigil
program
data
hemovigil
system
must
therefor
interpret
light
passiv
surveil
artifact
result
underreport
overal
advers
transfus
event
along
rel
overreport
specif
transfus
complic
medic
nurs
staff
becom
awar
one
time
anoth
compar
transfus
complic
influenti
public
literatur
highprofil
prevent
effort
initi
nation
blood
safeti
agenc
profession
societi
heighten
clinician
awar
specif
abt
complic
gener
diagnos
particular
abtrel
advers
event
report
event
hemovigil
system
fatal
report
us
fda
deem
transfus
relat
abt
deem
causal
contributori
role
death
report
unit
kingdom
seriou
hazard
transfus
shot
system
given
popul
unit
state
time
larger
popul
unit
kingdom
passiv
surveil
system
seem
record
similar
number
transfusionrel
death
per
million
popul
also
differ
frequenc
specif
caus
transfusionrel
death
fig
could
due
chanc
transfusionrel
death
captur
passiv
surveil
system
exceedingli
rare
event
nonetheless
transfusiontransmit
babesiosi
occur
unit
state
babesia
speci
endem
anddepend
assumpt
appropri
probabl
distribut
madeth
differ
mortal
trali
htr
probabl
exceed
figur
could
expect
sole
play
chanc
trali
htr
ta
rank
respect
first
second
third
fig
togeth
caus
death
account
fatal
report
us
fda
remain
death
due
transfusionassoci
circulatori
overload
taco
transfusiontransmit
babesiosi
anaphylaxi
graftvshost
diseas
gvhd
number
death
lead
caus
transfusionrel
mortal
unit
state
compar
trali
appear
displac
htr
lead
caus
transfusionrel
mortal
fig
fda
alert
transfus
medicin
profession
unit
state
possibl
transfus
patient
may
increas
risk
trali
octob
fda
receiv
report
transfusionrel
fatal
secondari
trali
andat
timetrali
thought
third
lead
caus
transfusionrel
mortal
unit
state
fda
receiv
report
trali
fatal
ascrib
increas
number
receiv
report
death
due
trali
better
recognit
report
trali
overal
limit
awar
trali
transfus
complic
clinic
entiti
separ
acut
respiratori
distress
syndrom
ardsfrom
trali
often
clinic
indistinguish
underscor
fact
trali
identifi
specif
transfus
complic
french
hemovigil
system
around
trali
awar
increas
public
associ
unit
kingdom
decis
convert
maleonli
ffp
mitig
risk
trali
octob
public
associ
canadian
consensu
confer
trali
conven
gener
standard
definit
trali
april
follow
promulg
consensu
criteria
diagnosi
trali
decemb
approxim
time
aabb
standard
blood
establish
limit
detect
bacteri
contamin
platelet
compon
becam
effect
march
variou
process
improv
also
implement
reduc
risk
ta
secondari
platelet
transfus
presum
increas
trali
awar
measur
reduc
ta
tempor
associ
increas
report
death
trali
well
reduct
report
death
ta
fig
awar
risk
ta
increas
culmin
fda
center
biolog
evalu
research
workshop
data
fatal
transfus
contamin
rbc
fatal
transfus
contamin
platelet
present
septemb
alreadi
risk
transfusiontransmit
hiv
hcv
infect
declin
aabb
alert
transfus
medicin
profession
risk
receiv
bacteri
contamin
platelet
might
higher
combin
risk
hiv
hepat
b
viru
hbv
hcv
human
tlymphotrop
viru
htlv
transmiss
transfus
reduct
report
death
ta
us
fda
start
evid
transfus
product
specif
singledonor
platelet
fig
march
autom
bacteri
cultur
system
avail
singledonor
platelet
collect
apheresi
hospit
releas
pool
whole
blood
year
number
death
report
due
trali
base
report
transfusionrel
fatal
made
us
fda
deriv
platelet
transfus
use
surrog
method
bacteri
detect
sensit
time
less
bacteri
cultur
accordingli
compli
spirit
rather
letter
march
aabb
standard
us
blood
establish
move
voluntarili
toward
provis
singledonor
rather
pool
whole
bloodderiv
platelet
transfus
thu
therapeut
platelet
dose
transfus
unit
state
provid
singledonor
platelet
novemb
virtual
ffp
transfus
unit
state
collect
male
donor
although
aabb
recommend
singledonor
platelet
collect
male
donor
femal
donor
without
histori
pregnanc
shown
wbc
antibodi
implement
novemb
origin
intend
report
unit
kingdom
shot
system
period
figur
show
mean
annual
number
death
deem
due
trali
base
report
transfusionrel
fatal
made
unit
kingdom
shot
program
zero
fatal
trali
vamvaka
blajchman
univers
comparison
transfusionrel
death
report
unit
kingdom
shot
system
due
trali
comparison
figur
obtain
differ
hemovigil
system
difficult
definit
transfus
complic
vari
system
sometim
also
report
facil
system
denomin
necessari
estim
risk
transfusionrel
death
often
unavail
inconsist
system
criteria
use
definit
probabl
possibl
attribut
death
abt
also
vari
thu
first
year
report
death
definit
probabl
possibl
attribut
abt
unit
kingdom
shot
system
death
due
trali
incorrect
blood
compon
transfus
categori
would
encompass
abo
htr
transfusionassoci
ta
gvhd
htr
ta
also
death
malaria
variant
creutzfeldtjakob
diseas
vcjd
posttransfus
purpura
infecti
caus
death
account
death
report
unit
kingdom
shot
program
death
report
fda
except
death
babesiosi
report
fda
death
malaria
death
vcjd
report
unit
kingdom
shot
death
infecti
caus
report
surveil
system
death
due
ta
anoth
analysi
fda
databas
biolog
product
deviat
report
advers
event
report
system
addit
fatal
report
increas
number
death
transfusiontransmit
babesiosi
would
therefor
increas
total
fig
even
correct
made
infecti
caus
death
account
transfusionrel
fatal
report
us
fda
last
year
thu
underreport
fatal
asid
death
infecti
caus
less
report
death
implement
bacteri
detect
platelet
low
frequenc
death
infecti
caus
partli
due
fact
number
shown
figur
obtain
hemovigil
program
although
transfusiontransmit
diseas
must
report
system
design
identifi
acut
advers
outcom
abt
captur
death
chronic
infect
acquir
abt
receiv
year
result
death
transfus
recipi
record
unit
kingdom
shot
system
death
transfusionacquir
vcjd
due
activ
surveil
effort
made
unit
kingdom
identifi
case
transmiss
vcjd
abt
thu
passiv
surveil
system
like
miss
even
acut
infect
transmit
abt
demonstr
ta
like
case
west
nile
viru
wnv
infect
occur
new
york
summer
transfusiontransmit
case
report
dengu
fever
viru
dfv
infect
occur
endem
area
mani
decad
effect
current
surveil
system
may
thu
low
particularli
point
recognit
event
physician
subsequ
report
transfus
servic
clinician
see
patient
dfv
infect
outbreak
unlik
consid
abt
possibl
sourc
patient
infect
obtain
critic
histori
recent
transfus
result
transmiss
dfv
abt
gone
undetect
recent
sinc
incid
hbv
hcv
hiv
infect
significantli
declin
blood
donor
better
predon
screen
criteria
also
decreas
incid
infect
gener
popul
report
fulmin
transfusiontransmit
hbv
infect
north
america
europ
minor
transfus
recipi
surviv
long
enough
develop
transfusionacquir
aid
cirrhosi
hepatocellular
carcinoma
due
chronic
hbv
hcv
infect
adult
tcell
leukemia
htlvassoci
myelopathi
risk
transmiss
hbv
infect
abt
higher
hcv
hiv
infect
like
remain
even
impend
implement
test
hbv
nucleic
acid
reduc
window
period
day
adult
infect
hbv
resolv
infect
chronic
carrier
rate
adult
sever
liver
diseas
occur
chronic
infect
person
sever
decad
later
immunocompromis
patient
infant
infect
transfus
may
higher
chronic
carrier
rate
well
higher
risk
develop
sever
diseas
gener
adult
popul
furthermor
despit
lack
hbv
surfac
antigen
detect
peripher
blood
hbv
dna
persist
decad
serum
liver
patient
clinic
import
find
remain
assess
longterm
studi
one
concern
remain
concern
benign
infect
may
becom
seriou
pathogen
transfus
recipi
render
immunocompromis
modern
medic
treatment
especi
immunosuppress
transfusiontransmit
agent
includ
cytomegaloviru
cmv
herpesvirus
human
parvoviru
babesia
speci
context
low
birth
weight
neonat
immunocompromis
patient
particular
risk
potenti
fatal
transfusionacquir
cmv
diseas
transmiss
latter
may
prevent
test
donor
cmv
antibodi
andor
remov
mononuclear
cell
harbor
cmv
viru
wbc
reduct
nonetheless
small
real
probabl
intract
risk
transmiss
remain
whether
cmvseroneg
wbcreduc
blood
compon
use
contemporari
risk
per
transfus
recipi
set
bone
marrow
transplant
thu
cmvseroneg
patient
enrol
studi
bowden
et
al
case
cmv
infect
death
cmv
diseas
three
death
could
definit
attribut
abt
occur
patient
develop
cmv
diseas
day
posttransplant
us
mosquitoborn
wnv
epidem
result
confirm
case
transfusiontransmit
wnv
infect
wnvrelat
death
test
wnv
nucleic
acid
introduc
north
america
juli
wnv
transmiss
death
occur
even
introduct
test
late
summer
risk
transfus
transmiss
wnv
may
high
per
sever
affect
geograph
region
even
though
transmiss
result
asymptomat
infect
number
vcjd
case
worldwid
bare
exceed
occur
unit
kingdom
vcjd
incid
appear
fall
mathemat
project
suggest
upper
limit
around
clinic
case
unit
kingdom
peopl
age
year
per
unit
kingdom
popul
may
incub
diseas
transmiss
spongiform
encephalopathi
vcjd
may
incub
period
year
infecti
particl
prion
potenti
circul
peripher
blood
much
presymptomat
phase
infect
thu
vamvaka
blajchman
measur
protect
blood
suppli
abnorm
proteinac
particl
vcjd
activ
evalu
unit
kingdom
implement
protect
measur
expect
near
futur
possibl
measur
includ
filtrat
blood
compon
prionretent
filter
andor
test
donor
blood
abnorm
conform
prion
protein
method
protein
misfold
cyclic
amplif
five
probabl
case
transfus
transmiss
vcjd
report
unit
kingdom
patient
receiv
blood
asymptomat
donor
later
develop
vcjd
donor
screen
protozo
transfusiontransmit
diseas
began
unit
state
introduct
test
trypanosoma
cruzi
although
variou
test
approach
alreadi
use
europ
case
transfusionacquir
malaria
report
unit
state
die
three
case
report
canada
endem
countri
risk
transmiss
high
case
per
million
rbc
unit
transfus
case
transfusiontransmit
malaria
occur
worldwid
although
report
case
may
repres
less
actual
case
furthermor
case
transfusiontransmit
babesiosisinclud
mani
fatal
report
unit
state
figur
captur
splenectom
immunocompromis
recipi
risk
sever
diseas
like
underestim
studi
endem
area
connecticut
estim
risk
transfus
transmiss
per
transfus
rbc
potenti
fatal
tti
includ
leishmaniasi
chaga
diseas
agent
even
transient
travers
human
circul
asymptomat
phase
infect
may
prove
transfus
transmiss
sixtyeight
potenti
known
transfusiontransmit
agent
priorit
aabb
task
forc
special
report
publish
juli
dramat
exampl
emerg
infect
appear
complet
new
infect
case
hiv
infect
latter
probabl
occur
result
crossspeci
transmiss
simian
immunodefici
virus
monkey
great
ape
human
origin
transmiss
probabl
occur
result
prepar
bushmeat
deriv
ape
anoth
caus
emerg
novel
agent
expans
exist
infect
larger
geograph
area
strike
exampl
expans
recent
appear
wnv
america
similar
manner
dfv
chikungunya
viru
may
well
expand
current
geograph
region
provid
agent
surviv
blood
compon
transmit
intraven
rout
infect
asymptomat
bloodborn
phase
potenti
transmiss
abt
possibl
exist
whether
infecti
phase
prolong
case
hiv
hbv
hcv
infect
short
case
wnv
dfv
infect
frequenc
infect
transmit
transfus
recipi
depend
length
asymptomat
bloodborn
phase
often
blood
donat
period
immun
statu
recipi
popul
aabb
task
forc
recent
priorit
potenti
known
transfusiontransmit
agent
base
exist
scientif
epidemiolog
evid
transmiss
abt
potenti
sever
clinic
outcom
could
result
public
attent
concern
four
prioriti
categori
assign
convey
particular
agent
signific
follow
white
yellow
orang
red
agent
includ
red
categori
vcjd
prion
dfv
babesia
speci
agent
includ
orang
categori
leishmania
speci
plasmodium
speci
trypanosoma
cruzi
chickungunya
viru
st
loui
enceph
viru
slev
except
last
agent
chickungunya
viru
slev
agent
priorit
red
orang
shown
transfus
transmit
focu
report
unit
state
protozoa
repres
major
transfus
risk
develop
countri
plasmodium
speci
trypanosoma
cruzi
place
categori
slevfor
evid
transmiss
transfus
endem
unit
state
chickungunya
viru
slev
task
forc
concern
agent
potenti
replic
wnv
us
experi
futur
concern
unit
state
task
forc
judg
medic
scientif
evid
transfusionrel
mortal
transmiss
babesia
speci
moder
high
wherea
evid
dfv
vcjd
prion
judg
low
nonetheless
concern
effect
develop
countri
medic
scientif
evid
transmiss
dfv
judg
moder
three
transfusiontransmit
agent
emerg
last
year
follow
hiv
vcjd
prion
wnv
therefor
prudenc
common
sens
assum
happen
past
happen
futur
worst
happen
hivlik
pathogen
long
incub
period
could
emerg
thatow
long
asymptomat
bloodborn
phasecould
accumul
signific
extent
blood
donor
popul
becom
recogn
therebi
almost
reach
preval
hiv
infect
us
blood
donor
popul
test
hiv
antibodi
introduc
year
test
us
blood
donor
hiv
infect
commencedth
preval
hiv
infect
donor
exceed
per
surveil
system
put
place
epidem
transfusionacquir
hiv
infect
unlik
new
viral
agent
caus
chronic
infect
could
go
undetect
long
hiv
went
undetect
therefor
infect
new
viral
agent
would
unlik
reach
preval
per
us
blood
donor
although
futur
hivlik
agent
would
certainli
detect
much
faster
hiv
recogn
still
possibl
thatbefor
measur
implement
interrupt
transmiss
abtth
futur
hivlik
agent
could
reach
preval
high
time
less
hiv
preval
thu
worst
case
scenario
strategi
reduc
abtrel
mortal
consist
model
possibl
hivlik
pathogen
reach
preval
per
us
blood
donor
measur
introduc
interrupt
transmiss
transfus
importantli
exclud
possibl
accumul
pathogen
us
blood
donor
popul
may
alreadi
start
occur
similarli
wnvlike
agent
chang
geograph
distribut
emerg
unit
state
transfusiontransmit
pathogen
caus
transmiss
abt
first
season
epidem
case
wnv
summer
hivlik
wnvlike
futur
pathogen
could
transmit
equal
effect
transfus
rbc
platelet
plasma
thu
risk
contract
tti
transfus
n
unit
exposur
n
donor
would
equal
p
n
p
perunit
probabl
transmiss
emerg
tti
transfus
risk
low
eg
per
case
futur
hivlik
agent
p
n
approxim
p
time
n
perrecipi
risk
calcul
multipli
perunit
risk
number
donor
recipi
expos
introduct
bacteri
detect
singledonor
apheresi
platelet
unit
state
march
ta
rank
third
among
caus
ta
fatal
report
fda
sinc
number
report
ta
death
reduc
less
half
fig
yet
ta
still
rank
third
among
caus
ta
fatal
fig
estim
incid
ta
vari
wide
approxim
per
transfus
platelet
pool
per
transfus
actual
bacteri
contamin
rate
blood
compon
substanti
higher
data
compil
mcdonald
blajchman
studi
singledonor
studi
pool
whole
bloodderiv
platelet
show
contamin
rate
respect
nearli
differ
presum
due
number
venipunctur
vs
involv
collect
singledonor
vs
pool
whole
bloodderiv
platelet
review
studi
rbc
contamin
rate
probabl
storag
temperatur
rbc
inhibit
bacteri
growth
storag
given
skin
bacteria
major
sourc
contamin
differ
measur
contamin
rate
store
compon
septic
reaction
transfus
patient
like
explain
lowlevel
contamin
evok
clinic
respons
concomit
antibiot
therapi
blunt
clinic
respons
andor
failur
correctli
attribut
sepsi
platelet
transfus
patient
neutropenia
fever
organ
caus
fatal
contamin
platelet
transfus
unit
state
franc
unit
kingdom
vamvaka
blajchman
case
gramposit
gramneg
organ
caus
episod
ta
howev
gramposit
gramneg
frequent
implic
organ
staphylococcu
epidermidi
escherichia
coli
staphylococcu
aureu
bacillu
cereu
organ
caus
fatal
contamin
rbc
transfus
gramneg
gramposit
overal
platelet
respons
fatal
rbc
storag
temperatur
platelet
wide
rang
bacteria
capabl
prolifer
level
colonyform
unitsml
growth
level
contamin
blood
compon
unit
lead
signific
morbid
mortal
shot
report
case
age
platelet
compon
known
episod
ta
occur
product
day
old
reduc
allow
storag
time
day
would
prevent
episod
would
like
result
suppli
problem
moreov
shot
fatal
due
platelet
compon
age
day
reduc
storag
time
would
prevent
fatal
case
european
center
introduct
bacteri
detect
platelet
use
autom
cultur
system
enabl
storag
time
extend
day
us
fda
allow
storag
time
platelet
extend
day
soon
return
shelf
life
back
day
report
increas
incid
fatal
ta
episod
recent
experiment
protocol
consid
extens
storag
time
platelet
day
introduct
autom
bacteri
cultur
system
halt
unit
state
increas
incid
ta
relationship
prolong
storag
increas
risk
ta
report
rbc
contamin
yersinia
enterocolitica
yersinia
grow
well
use
citrat
preserv
solut
sourc
energi
owe
lack
siderophor
requir
iron
optimum
growth
store
rbc
thu
provid
ideal
growth
medium
microorgan
almost
seriou
reaction
rbc
contain
enterocolitica
rbc
store
week
around
improv
donor
select
intend
exclud
prospect
donor
bacteremia
improv
donor
arm
disinfect
divers
initi
flow
donor
blood
presum
contain
skin
contamin
collect
bag
pouch
overnight
hold
collect
whole
blood
andor
wbc
reduct
reduc
elimin
risk
bacteri
contamin
blood
compon
aabb
requir
measur
limit
detect
bacteri
contamin
platelet
compon
time
suitabl
autom
bacteri
cultur
system
avail
apheresi
platelet
unit
state
sinc
becom
avail
use
pool
whole
bloodderiv
platelet
well
risk
sampl
error
even
sensit
method
current
avail
autom
bacteri
cultur
test
clinic
sensit
less
although
bacteri
detect
system
excel
analyt
sensit
owe
exceedingli
low
start
concentr
bacteria
platelet
compon
possibl
submit
cultur
small
volum
ml
platelet
product
may
contain
bacteria
american
red
cross
arc
perform
bacteri
cultur
test
million
singledonor
platelet
donat
confirm
posit
cultur
result
transfus
associ
compon
prevent
period
howev
episod
ta
secondari
screen
singledonor
platelet
report
includ
fatal
per
distribut
compon
ta
episod
associ
compon
store
day
comparison
risk
ta
tasrel
death
singledonor
platelet
implement
bacteri
cultur
test
singledonor
platelet
indic
decreas
report
event
per
vs
per
fatal
per
vs
per
compon
clinic
implic
declin
trend
p
unclear
could
reflect
poor
sensit
autom
bacteri
cultur
system
increas
recognit
report
ta
time
like
meant
risk
ta
march
greater
gener
appreci
time
also
signific
risk
remain
despit
implement
bacteri
cultur
system
reaction
fatal
introduct
bacteri
cultur
test
also
report
blood
system
avail
cultur
system
canada
ta
episod
fatal
among
recipi
cultur
singledonor
platelet
report
result
singledonor
platelet
arc
conduct
followup
studi
optim
collect
condit
doubl
ml
ml
volum
sampl
submit
cultur
report
rate
event
per
differ
significantli
previou
period
per
interestingli
cultureneg
singledonor
compon
passiv
report
arc
caus
ta
latter
period
anoth
estim
magnitud
risk
report
john
hopkin
hospit
maintain
activ
surveil
ta
one
per
cultureneg
singledonor
platelet
compon
caus
ta
march
august
episod
ta
occur
studi
howev
predat
process
improv
implement
arc
studi
compar
frequenc
bacteri
contamin
pool
whole
bloodderiv
singledonor
platelet
set
implement
bacteri
cultur
test
compon
simultan
subject
metaanalysi
across
studi
conduct
unit
state
pool
whole
bloodderiv
platelet
concentr
higher
frequenc
bacteri
contamin
singledonor
platelet
summari
odd
ratio
confid
interv
ci
p
b
contrast
across
studi
conduct
europ
differ
risk
bacteri
contamin
pool
whole
bloodderiv
singledonor
platelet
summari
ci
p
n
subset
studi
highli
homogen
statist
p
n
q
test
statist
despit
fact
process
compon
collect
prepar
well
cultur
condit
sampl
volum
use
anaerob
bottl
criteria
determin
trueposit
result
differ
across
studi
whether
differ
find
analys
due
differ
method
platelet
prepar
plateletrich
plasma
platelet
unit
state
vs
buffi
coat
platelet
europ
factor
associ
method
platelet
prepar
eg
overnight
hold
collect
whole
blood
europ
could
determin
metaanalysi
method
platelet
prepar
overlap
sourc
heterogen
theoret
justif
lower
bacteri
risk
associ
buffi
coat
platelet
advanc
synthesi
studi
could
undertaken
owe
signific
statist
p
b
q
test
statist
medic
heterogen
result
metaanalysi
concern
differ
risk
pool
whole
bloodderiv
singledonor
platelet
unit
state
would
expect
differ
number
venipunctur
done
figur
combin
variou
publish
estim
find
metaanalysi
deriv
estim
risk
ta
associ
pool
whole
bloodderiv
vs
singledonor
platelet
manufactur
unit
state
bestcas
scenario
ie
assum
pool
whole
bloodderiv
platelet
distribut
unit
therapeut
platelet
dose
current
soon
prepool
cultur
transfusionrel
acut
lung
injuri
emerg
lead
caus
transfusionrel
mortal
unit
state
fig
transfusionrel
acut
lung
injuri
new
ali
occur
within
hour
transfus
clear
tempor
relationship
transfus
patient
without
risk
factor
ali
transfus
thu
canadian
consensu
confer
definit
trali
base
americaneuropean
consensu
confer
definit
ali
tempor
relationship
transfus
definit
ali
requir
possibl
circulatori
overload
ie
left
atrial
hypertens
rule
circulatori
overload
exclud
howev
consensu
definit
trali
allow
diagnosi
possibl
trali
made
case
patient
risk
factor
ali
tempor
vamvaka
blajchman
relat
transfus
latter
includ
sepsi
aspir
pneumonia
toxic
inhal
lung
contus
near
drown
multipl
trauma
burn
injuri
acut
pancreat
cardiopulmonari
bypass
drug
overdos
transfusionrel
acut
lung
injuri
clinic
present
mirror
ard
abt
contrast
ard
howev
patient
trali
typic
recov
resolut
pulmonari
infiltr
within
hour
case
fatal
ratio
avoid
spuriou
associ
trali
transfus
blood
compon
collect
femal
donor
donor
circul
wbc
antibodi
diagnost
suspicion
bia
trali
wbcantibodi
test
femal
donor
show
wbc
antibodi
plasma
donor
compon
given
patient
ali
presenc
risk
factor
ali
fig
diagnosi
trali
made
sole
basi
clinic
present
regardless
laboratori
test
follow
result
incid
trali
unknown
standard
definit
avail
rel
recent
earli
report
quot
incid
per
transfus
blood
compon
subsequ
report
rang
per
platelet
pool
per
rbc
trali
report
use
type
blood
compon
blood
compon
implic
publish
casereport
small
caseseri
contain
ml
plasma
ffp
frequent
implic
compon
howev
trali
also
occur
wholebloodderiv
platelet
compon
contain
littl
ml
plasma
importantli
literatur
indic
ffp
compon
contain
larg
volum
plasma
princip
culprit
theori
trali
pathogenesi
transfusionrel
acut
lung
injuri
due
wbc
antibodi
solubl
biolog
respons
mediat
accumul
storag
cellular
blood
compon
still
unidentifi
agent
contain
transfus
blood
compon
wbc
antibodi
transfus
plasma
direct
recipi
wbc
antigen
interact
antigen
patient
wbc
microcircul
lung
neutrophilspecif
antibodi
especi
antibodi
human
neutrophil
appear
relev
nonetheless
presenc
wbc
antibodi
donor
predict
occurr
trali
depict
histor
risk
repres
empir
data
set
febril
reaction
platelet
monitor
cultur
estim
current
risk
base
assumpt
whole
bloodderiv
platelet
distribut
unit
state
soon
prestoragepool
cultur
estim
risk
contemporari
octob
settingwhen
surrog
method
rather
bacteri
cultur
usual
use
screen
pool
whole
bloodderiv
platelet
bacteriase
vamvaka
transfusionrel
mortal
recipi
wbc
antibodi
infus
caus
trali
make
possibl
alloantibodiesalbeit
present
trali
casescould
surrog
anoth
etiolog
factor
clinic
evid
relat
trali
wbc
antibodi
inde
explain
spuriou
associ
shown
figur
link
trali
wbc
antibodi
remain
circumstanti
support
antibodi
hypothesi
trali
pathogenesi
infus
wbc
antibodi
ex
vivo
anim
model
precipit
trali
absenc
factor
precipit
trali
specif
crossov
rct
icu
patient
show
impair
pulmonari
function
occur
frequent
patient
receiv
ffp
multipar
women
vs
control
convers
maleonli
ffp
unit
kingdom
observ
studi
multitranfus
patient
undergo
abdomin
aortic
aneurysm
repair
demonstr
reduc
risk
hypoxia
maleonli
ffp
administ
prospect
observ
studi
compar
recipi
maleonli
ffp
recipi
mix
ie
male
femal
ffp
japan
observ
develop
pulmonari
distressdefin
pao
fraction
multitransfus
patient
like
receiv
blood
compon
previous
pregnant
femal
donor
recipi
like
found
receiv
compon
donor
whose
plasma
contain
wbc
antibodi
regardless
whether
trali
present
therefor
femal
donor
wbc
antibodi
like
spurious
associ
trali
result
laboratori
test
consid
make
diagnosi
spuriou
associ
may
origin
trali
case
includ
seri
compil
blood
supplier
basi
passiv
surveil
report
receiv
hospit
recipi
serum
longer
obtain
reason
consensu
criteria
requir
diagnosi
trali
made
clinic
without
consid
result
laboratori
test
provid
diagnosi
trali
made
manner
design
alloimmun
trali
reserv
case
proven
wbc
incompat
implic
donor
relev
cognat
recipi
wbc
antigen
case
common
wbc
antigen
antibodi
even
wbc
incompat
implic
donor
recipi
occur
chanc
thu
although
wbc
incompat
strengthen
belief
correct
diagnosi
appropri
clinic
set
use
basi
diagnosi
vamvaka
blajchman
inspir
oxygen
ratio
less
subject
within
hour
transfus
patient
possibl
trali
taco
appar
pulmonari
edema
receipt
maleonli
ffp
associ
reduct
p
risk
pulmonari
distress
howev
subject
receiv
maleonli
ffp
vs
patient
receiv
mix
ffp
develop
possibl
trali
p
wbc
antibodi
associ
develop
trali
univariatealbeit
multivariateanalys
hitherto
report
prospect
observ
studi
includ
consecut
transfus
patient
studi
therefor
suggest
maleonli
ffp
advantag
posttransfus
pulmonari
function
although
patientrel
factor
sepsi
fluid
balanc
oppos
receipt
femal
ffp
primari
determin
ali
multiplytransfus
patient
fact
altern
addit
wbc
antibodi
model
propos
silliman
et
al
may
explain
develop
trali
transfus
recipi
variou
preexist
risk
factor
ali
initi
insult
vascular
endothelium
due
infect
surgeri
trauma
massiv
transfus
attract
prime
neutrophil
adher
endothelium
second
hit
mediat
biolog
respons
modifi
contain
transfus
plasma
eg
lipidprim
molecul
found
plasma
supernat
store
oppos
fresh
rbc
platelet
cytokin
ligand
andor
wbc
antibodi
molecul
activ
sequest
neutrophil
releas
oxidas
proteas
damag
endothelium
produc
capillari
leak
ali
rat
model
demonstr
trali
result
event
first
clinic
condit
patient
second
consist
antibodi
prime
neutrophil
andor
plasma
store
blood
find
complet
prospect
observ
studi
underscor
role
patientrel
factor
also
consist
bioactivelipidneutrophilprim
hypothesi
diagnost
criteria
trali
requir
altern
risk
factor
ali
exclud
diagnosi
trali
could
made
virtual
case
trali
mediat
mechan
would
diagnos
trali
approach
diagnosi
may
explain
high
preval
wbc
antibodi
well
femal
sex
donor
implic
blood
compon
fig
literatur
trali
accordingli
canadian
consensu
criteria
permit
diagnosi
possibl
trali
patient
risk
factor
ali
yet
clinic
set
make
diagnosi
trali
like
consensu
criteria
adher
howev
mani
clinician
laboratorian
dissuad
make
diagnosi
trali
either
absenc
donor
wbc
antibodi
presenc
altern
risk
factor
ali
hard
determin
impact
diagnost
bias
may
collect
case
report
small
case
seri
compris
literatur
trali
approach
trali
prevent
canadian
consensu
panel
note
hypothes
caus
trali
suggest
differ
strategi
prevent
antibodi
hypothesi
support
exclus
plasma
donor
pathogen
antibodi
wherea
bioactivelipidneutrophilprim
hypothesi
support
reduct
length
storag
wash
cellular
blood
compon
regardless
donor
characterist
consensu
panel
note
prevent
strategi
potenti
reduc
blood
suppli
exclud
safe
donor
accord
antibodi
hypothesi
trali
pathogenesi
safe
product
accord
bioactivelipidneutrophilprim
hypothesi
hitherto
countri
appear
implement
reduct
length
storag
wash
cellular
blood
compon
reduc
risk
trali
follow
unit
kingdom
sever
european
countri
well
unit
state
canada
convert
maleonli
ffp
risk
reduct
strategi
countri
howev
yet
convert
singledonor
platelet
suppli
collect
sole
male
donor
femal
donor
without
histori
pregnanc
shown
wbc
antibodi
us
leukocyt
antibodi
preval
studi
enrol
femal
donor
transfus
male
donor
nontransfus
male
donor
use
valid
questionnair
elicit
histori
pregnanc
includ
miscarriag
termin
hla
antibodi
detect
femal
histori
pregnanc
femal
never
pregnant
nontransfus
male
transfus
male
femal
never
pregnant
nontransfus
male
transfus
male
preval
hla
antibodi
transfus
alon
result
increas
preval
hla
antibodi
howev
time
sinc
last
transfus
donor
enrol
leukocyt
antibodi
preval
studi
long
median
year
studi
evalu
recent
transfus
donor
might
circul
hla
antibodi
even
antibodi
fall
undetect
level
matter
month
abt
reason
respect
preval
hla
antibodi
nontransfus
male
neverpregn
femal
uncertain
could
repres
falseposit
result
antibodi
crossreact
bacteri
antigen
immun
associ
vaccin
impact
canadian
consensu
criteria
diagnos
trali
unit
kingdom
shot
system
use
canadian
consensu
criteria
diagnos
trali
therebi
perhap
exclud
case
wbc
antibodi
demonstr
releg
possibl
trali
categori
similarli
year
public
consensu
definit
us
hospit
base
diagnos
trali
combin
clinic
serolog
find
workup
regularli
includ
hla
class
ii
antibodi
sometim
neutrophil
antibodi
well
donor
screen
wbc
antibodi
often
hing
donor
sex
polici
bear
diagnosi
trali
decid
casebycas
basi
figur
show
histor
approach
diagnosi
would
produc
associ
femal
sex
wbc
antibodi
clinic
diagnos
trali
well
report
trali
literatur
even
recent
literatur
howev
canadian
consensu
definit
consist
adher
exampl
recent
rct
efficaci
wbcreduc
blood
compon
prevent
trali
none
diagnos
trali
assign
either
arm
trial
pertain
ali
occur
within
hour
abt
ali
common
critic
ill
multitransfus
patient
mani
case
ali
misdiagnos
trali
tempor
associ
transfus
demonstr
wbc
incompat
implic
donor
recipi
oppos
mere
presenc
wbc
antibodi
implic
donor
serum
strengthen
evid
particular
case
ali
consensu
criteria
met
diagnosi
trali
made
laboratori
workup
repres
trali
howev
whether
trali
mediat
pathogenet
mechan
distinct
gener
mechan
ali
remain
unknown
even
canadian
consensu
criteria
adher
diagnosi
trali
repres
best
clinic
judgment
rather
firm
diagnosi
buttress
pathognomon
diagnost
test
criteria
broad
subject
specifi
princip
differenti
diagnosi
taco
made
trali
routin
clinic
set
subject
natur
diagnosi
highlight
clinic
serolog
document
case
trali
meet
consensu
definit
report
fortynin
case
trali
diagnos
netherland
januari
juli
adher
strictli
canadian
consensu
criteria
perform
complet
trali
workup
includ
test
wbc
antibodi
sera
implic
donor
wbc
incompat
test
implic
donor
recipi
patient
underw
complet
laboratori
workup
purpos
make
diagnosi
trali
per
se
identifi
subcategori
case
alloimmun
trali
case
least
one
implic
donor
wbc
antibodi
case
serolog
incompat
demonstr
least
one
donor
recipi
ie
donor
antibodi
direct
cognat
wbc
antigen
recipi
case
alloimmun
trali
demonstr
sever
morbid
compar
remain
case
although
mortal
increas
two
hundr
fiftynin
compon
benefit
convert
maleonli
ffp
thu
like
significantli
smaller
predict
unit
kingdom
shot
system
report
fig
earlier
case
seri
although
consensu
appropri
convert
maleonli
ffp
achiev
studi
shown
reduct
risk
trali
avoid
femal
donor
adduc
evid
support
thesi
measur
enhanc
blood
safeti
gajic
et
al
present
prospect
cohort
studi
patient
sequenti
admit
medic
icu
evalu
trali
base
canadian
consensu
criteria
captur
suspect
trali
case
identifi
preexist
risk
factor
ali
possibl
trali
case
least
one
altern
risk
factor
ali
present
seventyfour
patient
develop
trali
anoth
risk
factor
ali
highlight
interact
abt
patient
factor
develop
trali
find
underscor
risk
ard
diagnos
either
ali
trali
critic
ill
patient
preexist
risk
factor
ali
receiv
transfus
even
singleunit
blood
gajic
et
al
compar
trali
case
control
drawn
among
patient
develop
worsen
respiratori
statu
within
hour
abt
case
receiv
unit
femal
donor
donor
pregnanc
well
ffp
ffp
femal
donor
pregnanc
contrast
number
rbc
transfus
differ
case
control
wbc
antibodi
bioactiv
lipid
accumul
storag
higher
compon
receiv
case
control
thu
gajic
et
al
conclud
although
sepsi
risk
factor
commonli
associ
diagnos
ali
popul
critic
ill
patient
modifi
transfus
factor
ie
donor
sex
pariti
wbc
alloimmun
also
associ
trali
indic
opportun
prevent
wbc
antibodi
associ
trali
multivari
analysi
includ
variou
patientrel
risk
factor
ali
yet
straightforward
opportun
trali
prevent
would
exclus
femal
donor
make
donat
ffp
magnitud
benefit
deriv
convers
maleonli
ffp
remain
determin
improv
blood
safeti
even
small
suggest
dutch
data
ie
prevent
overal
trali
case
overal
trali
death
would
make
convers
maleonli
ffp
worthwhil
blood
safeti
measur
htr
transfus
donor
rbc
attack
recipi
natur
occur
antibodi
abo
antigen
andor
antibodi
rbc
antigen
produc
immun
previou
transfus
pregnanc
acut
htr
occur
within
hour
abt
althoughin
case
aboincompat
transfusionit
usual
begin
transfus
delay
htr
dhtr
begin
anamnest
secondari
immun
respons
donor
rbc
antigen
recipi
alloimmun
previou
transfus
pregnanc
clinic
signific
rbc
alloantibodi
nonabo
antigen
disappear
time
predispos
transfus
recipi
develop
dhtr
rare
dhtr
caus
death
although
death
report
outcom
transfusionrel
mortal
immedi
htr
depend
potenc
usual
abo
recipi
antibodi
volum
blood
transfus
infus
rate
may
also
factor
fatal
associ
transfus
ml
mortal
approach
transfus
exceed
ml
fatal
report
fda
htr
due
abo
incompat
commonest
caus
htr
failur
identifi
intend
recipi
correctli
incorrect
blood
compon
transfus
occur
oper
room
death
report
fda
ident
figur
calcul
french
hemovigil
data
per
million
transfus
rbc
ci
per
million
per
similar
figur
per
million
compon
issu
transfus
obtain
shot
system
death
abo
htr
proper
identif
transfus
recipi
time
transfus
pretransfus
blood
specimen
time
specimen
collect
critic
prevent
abo
htr
human
error
caus
transfus
wrong
unit
miscollect
mislabel
pretransfus
specimen
therefor
administr
system
develop
analyz
error
prevent
futur
recurr
moreov
proper
identif
transfus
recipi
crucial
barrier
system
intend
physic
prevent
transfus
blood
without
correct
identif
patient
devis
includ
plastic
lock
must
unlock
entri
correct
identif
code
use
special
wristband
identif
transfus
recipi
multipl
barcod
patient
wristband
blood
sampl
tube
blood
compon
bag
nurs
identif
badg
along
pointoftransfus
read
devic
verifi
ident
well
similar
approach
tool
requir
invest
inform
technolog
integr
system
medic
administr
guard
miscollect
mislabel
pretransfus
specimen
us
transfus
servic
requir
verif
recipi
abo
group
collect
independ
pretransfus
sampl
figur
show
reduct
avoid
death
abo
htr
report
us
fda
recent
decreas
death
tempor
associ
februari
fda
requir
machineread
inform
includ
blood
contain
label
april
similar
reduct
aborel
fatal
recent
record
unit
kingdom
shot
system
death
nonabo
htr
despit
reduct
abo
fatal
mean
annual
number
death
acut
htr
remain
stabl
fig
report
fatal
due
acut
htr
secondari
nonabo
antibodi
increas
recent
year
increas
number
report
fda
probabl
reflect
improv
awar
potenti
nonabo
htr
caus
death
nonabo
antibodi
implic
fatal
htr
implic
rbc
antibodi
includ
jk
b
jk
kell
fy
fy
b
e
js
well
multipl
antibodi
specif
although
possibl
consid
format
rbc
alloantibodi
may
repres
random
process
appear
case
nonchron
transfus
patient
receiv
rbc
match
abo
antigen
form
rbc
alloantibodi
format
first
rbc
alloantibodi
identifi
patient
high
respond
subsequ
rbc
alloantigen
challeng
thu
patient
alreadi
form
rbc
alloantibodi
probabl
form
addit
rbc
antibodi
rbc
transfus
remark
probabl
hematooncolog
nonhematooncolog
patient
despit
fact
hematooncolog
patient
receiv
intens
immunosuppress
treatment
retrospect
cohort
studi
shonewil
et
al
span
period
approxim
year
hematooncolog
patient
receiv
rbc
unit
abt
episod
u
episod
nonhematooncolog
patient
u
episod
addit
rbc
alloantibodi
detect
howev
hematooncolog
patient
experi
multipl
transfus
event
short
period
probabl
caus
overestim
number
transfus
need
addit
antibodi
format
hematooncolog
patient
compar
obstetr
surgic
medic
patient
current
standard
care
requir
provis
aboand
dmatch
rbc
patient
made
alloantibodi
rbc
antigen
patient
form
alloantibodi
transfus
rbc
must
neg
antigen
prospect
recipi
detect
antibodi
thu
multipl
antibodi
present
process
form
complex
serolog
workup
necessari
compat
rbc
unit
issu
blood
bank
antibodi
detect
method
capabl
identifi
clinic
signific
rbc
alloantibodi
howev
acut
htr
still
occur
either
clinic
signific
rbc
alloantibodi
miss
fulli
compat
rbc
unit
avail
need
case
hemolysi
transfus
rbc
preexist
rbc
alloantibodi
nonabo
antigen
caus
morbid
mortal
current
identifi
patient
respond
rbc
transfus
format
rbc
alloantibodi
patient
hemoglobinopathi
especi
prone
form
multipl
alloantibodi
gener
complex
serolog
workup
caus
delay
provis
compat
blood
along
delay
htr
sometim
also
acut
htr
prevent
problem
standard
care
elev
mani
us
hospit
patient
hemoglobinopati
multiplytransfus
patient
receiv
unit
match
c
e
k
sometim
also
jk
fy
antigen
prevent
format
alloantibodi
antigen
extend
antigen
match
donor
recipi
gener
perform
phenotyp
use
tradit
serolog
techniqu
hemagglutin
drive
forc
extend
antigen
match
patient
hemoglobinopathi
differ
donor
recipi
phenotyp
due
ethnicpool
gene
divers
extend
phenotyp
antigen
match
gener
perform
multiplytransfus
patient
either
clinic
benefit
elev
standard
care
empir
document
addit
effort
gener
extend
phenotyp
match
consid
prohibit
genotyp
c
e
k
jk
fy
clinic
signific
rbc
antigen
avail
howev
perform
patient
well
donor
unit
use
dna
extract
residu
wbc
wbcreduc
rbc
unit
feasibl
provid
extend
antigen
match
donor
recipi
genotyp
recent
demonstr
multicent
us
studi
sever
categori
patient
addit
patient
sickl
cell
diseas
studi
use
randomdonor
unit
exist
inventori
use
computer
inventori
manag
system
creat
maintain
inventori
genotyp
unit
well
identifi
compat
blood
transfus
recipi
increasingli
stringent
level
antigen
match
transfusionassoci
gvhd
result
engraft
donor
lymphocyt
prolifer
mount
immun
attack
recipi
destroy
recipi
tissu
diseas
fatal
immunocompromis
patient
clear
donor
lymphocyt
patient
receiv
blood
compon
transfusionrel
mortal
donor
eg
rel
partial
share
hla
haplotyp
risk
gvhd
must
receiv
irradi
compon
irradi
alway
prevent
gvhd
yet
sporad
case
occur
fatal
case
captur
shot
system
although
case
univers
wbc
reduct
implement
case
patient
known
immunocompromis
time
transfus
bcell
malign
list
indic
irradi
unit
kingdom
appar
immunocompet
although
may
partial
haplotyp
share
donor
recipi
higher
risk
tagvhd
report
japan
popul
racial
homogen
like
share
hla
haplotyp
four
patient
receiv
fresh
blood
cardiac
surgeri
develop
tagvhd
rososhanski
et
al
estim
per
patient
transfus
unit
state
may
share
hla
haplotyp
donor
figur
far
higher
report
number
tagvhd
case
perhap
blood
transfus
unit
state
contain
viabl
lymphocyt
hospit
especi
cancer
pediatr
center
irradi
blood
transfus
patient
patient
risk
tagvhd
may
receiv
irradi
blood
due
error
consensu
list
condit
render
patient
risk
tagvhd
appar
immunocompet
patient
develop
tagvhd
wbcreduc
compon
elimin
risk
tagvhd
although
may
possibl
develop
wbc
reduct
technolog
futur
capabl
recognit
taco
improv
death
attribut
taco
fda
make
taco
fourth
frequent
caus
report
transfusionrel
death
fig
patient
diminish
cardiac
reserv
chronic
anemia
rapid
transfus
precipit
acut
pulmonari
edema
secondari
congest
heart
failur
even
small
transfus
volum
may
caus
taco
especi
infant
elderli
transfusionassoci
circulatori
overload
report
occur
per
transfus
patient
even
patient
transfus
icu
variou
potenti
fatal
reaction
occur
within
hour
transfus
includ
anaphylaxi
ta
hypotens
bleed
associ
dilut
platelet
clot
factor
metabol
disord
other
anaphylaxi
trigger
protein
contain
transfus
donor
plasma
caus
fatal
patient
iga
defici
preform
antiiga
antibodi
patient
must
receiv
compon
collect
igadefici
donor
posttransfus
purpura
sudden
dramat
thrombocytopenia
develop
abt
patient
previous
sensit
pregnanc
transfus
blood
compon
usual
transfus
rbc
highfrequ
plateletspecif
antigen
donor
anamnest
immun
respons
produc
potent
antibodi
paradox
destroy
recipi
antigenneg
platelet
addit
donor
antigenposit
platelet
histor
mortal
although
recent
fatal
among
case
captur
shot
system
year
studi
detect
relationship
periop
rbc
transfus
higher
target
hematocrit
improv
clinic
outcom
larg
retrospect
cohort
studi
suggest
rbc
transfus
may
result
lower
mortal
elderli
patient
acut
myocardi
infarct
subject
admit
hematocrit
less
surviv
less
day
observ
reanalysi
patient
acut
coronari
syndrom
enrol
drug
rct
show
transfus
patient
higher
mortal
untransfus
subject
tricc
rct
found
compar
restrict
rbc
transfus
strategi
liber
strategi
may
associ
increas
inhospit
mortal
normovolem
critic
ill
patient
fig
investig
random
icu
patient
restrict
strategi
arm
vamvaka
blajchman
patient
liber
strategi
arm
former
patient
transfus
hemoglobin
concentr
fell
gdl
less
latter
fell
gdl
less
patient
alloc
restrict
strategi
arm
receiv
averag
fewer
rbc
unit
liber
strategi
arm
mean
sd
vs
rbc
per
patient
overal
vs
patient
respect
avoid
abt
altogeth
p
b
primari
outcom
mortal
restrict
strategi
arm
compar
liber
strategi
arm
p
adjust
multipl
organ
dysfunct
score
mod
differ
arm
mean
sd
vs
respect
p
chang
score
baselin
vs
respect
p
mortal
entir
hospit
significantli
lower
restrict
strategi
arm
vs
p
absolut
risk
differ
inhospit
mortal
arm
ci
p
compar
restrict
strategi
arm
liber
strategi
arm
also
experienc
wors
outcom
risk
myocardi
infarct
pulmonari
edema
fig
three
patient
restrict
strategi
arm
compar
subject
liber
strategi
arm
develop
myocardi
infarct
p
also
patient
restrict
strategi
arm
compar
subject
liber
strategi
arm
develop
pulmonari
edema
p
b
although
greater
risk
pulmonari
edema
liber
strategi
arm
could
explain
fluid
overload
caus
rbc
transfus
find
contradict
would
expect
liber
transfus
strategi
result
improv
oxygen
deliveri
myocardium
enhanc
oxygen
consumpt
myocardium
produc
improv
myocardi
function
murphi
et
al
link
unit
kingdom
popul
regist
clinic
icu
blood
bank
databas
patient
undergon
cardiac
surgeri
year
transfus
untransfus
patient
compar
adjust
confound
factor
abt
found
associ
higher
risk
earli
late
mortal
ischem
postop
morbid
similarli
observ
studi
patient
netzer
et
al
found
abt
patient
ali
associ
increas
inhospit
mortal
nonwbcreduc
wbcreduc
abt
associ
signific
p
b
increas
mortal
although
magnitud
increas
risk
greater
nonwbcreduc
rather
wbcreduc
rbc
use
sever
preclin
clinic
observ
support
hypothesi
abt
gener
nonwbcreduc
abt
particular
may
associ
multipl
organ
failur
mof
mechan
underli
differ
primari
outcom
mortal
one
mortal
outcom
report
author
inhospit
mortal
approach
statist
signific
p
find
confirm
futur
rct
would
suggest
everi
transfus
critic
ill
patient
might
die
excess
rbc
transfus
receiv
per
liber
compar
restrict
criteria
develop
mof
unclear
evid
suggest
tissu
injuri
mediat
reactiv
oxygen
speci
proteolyt
enzym
releas
activ
neutrophil
abt
neutrophilprim
effect
report
associ
abt
shortterm
mortal
could
reflect
proinflammatori
effect
abt
parallel
bioactivelipidneutrophilprim
effect
postul
pathogenesi
trali
silliman
et
al
propos
abt
may
exercis
neutrophilprim
effect
mediat
bioactiv
lipid
accumul
storag
postul
rapidli
deterior
wbc
store
rbc
releas
cytotox
enzym
may
act
fragment
rbc
membran
produc
mediat
respons
neutrophil
prime
endotheli
cell
activ
investig
demonstr
plasma
obtain
store
rbc
prime
neutrophil
superoxid
product
enhanc
cytotox
also
activ
pulmonari
endotheli
cell
doseand
agedepend
fashion
length
rbc
storag
import
studi
evid
neutrophil
prime
obtain
plasma
store
short
period
use
similarli
chinye
et
al
report
plasma
supernat
store
rbc
activ
neutrophil
wherea
wbc
reduct
rbc
unit
abrog
effect
studi
johnson
et
al
patient
receiv
allogen
rbc
significantli
higher
risk
mof
recipi
polymer
hemoglobin
neutrophil
obtain
recipi
rbc
demonstr
prime
evidenc
increas
integrin
express
superoxid
product
elastas
releas
neutrophil
obtain
recipi
polymer
hemoglobin
show
evid
prime
studi
investig
benefit
obtain
place
wbc
reduct
filter
arteri
line
cardiopulmonari
bypass
circuit
suggest
nonwbcreduc
abt
may
provok
cardiac
andor
pulmonari
failur
furthermor
associ
abt
prolong
mechan
ventil
mof
report
observ
studi
rbc
transfus
subject
enrol
tricc
rct
nonwbcreduc
plausibl
reason
increas
inhospit
mortal
fig
mod
specif
complic
fig
could
involv
pathophysiolog
mechan
reli
either
wbc
rbc
particular
situat
critic
ill
patient
system
inflammatori
respons
syndrom
sir
oxid
stress
enrol
tricc
rct
forcevil
et
al
invok
potenti
deleteri
effect
ironcontain
protein
hemoglobin
suppli
transfus
rbc
reason
rbc
contain
iron
amplifi
oxid
stress
increas
oxygen
deliveryth
purpos
rbc
transfusionin
patient
sir
may
also
increas
product
toxic
reactiv
oxygen
speci
consequ
excess
product
reactiv
oxygen
speci
subject
liber
transfus
arm
receiv
rbc
unit
mg
extra
iron
compar
total
bodi
iron
g
may
worsen
preexist
oxid
stress
comparison
figur
show
advers
outcom
patient
restrict
compar
liber
transfus
strategi
arm
surround
ci
ci
includ
null
valu
correspond
statist
signific
ie
p
n
categori
comparison
report
author
number
organ
fail
vs
septic
shock
catheterrel
sepsi
pneumonia
occur
less
frequent
liber
compar
restrict
strategi
arm
differ
minim
differ
septic
shock
approach
trend
p
differ
categor
outcom
favor
restrict
strategi
arm
differ
cardiac
complic
p
b
myocardi
infarct
p
pulmonari
edema
p
b
statist
signific
wherea
differ
ard
p
approach
signific
five
outcom
analyz
continu
variabl
favor
restrict
strategi
arm
three
differ
minim
differ
adjust
mod
p
chang
baselin
score
p
statist
signific
one
unit
blood
contain
time
quantiti
iron
absorb
daili
diet
mg
vs
bit
mg
iron
overload
toxic
multipl
rbc
transfus
well
document
patient
transfusiondepend
anemia
requir
u
rbc
per
month
would
receiv
uy
u
year
therebi
accumul
g
iron
herhi
bodi
transfus
rbc
rel
short
life
span
compar
approxim
life
span
normal
rbc
transfus
rbc
undergo
erythrophagocytosi
releas
iron
eventu
overload
macrophag
excess
iron
reenter
plasma
overwhelm
ironcarri
capac
transferrin
deposit
tissu
free
iron
increas
iron
level
becom
detect
day
rbc
transfus
iron
overload
longterm
transfus
damag
liver
heart
pancrea
thyroid
endocrin
gland
forcevil
et
al
therefor
posit
thatin
set
sir
defici
antioxid
system
overwhelm
haptoglobinhemopexintransferrin
system
could
potenti
case
critic
ill
icu
patient
enrol
tricc
rct
increas
iron
burden
excess
rbc
transfus
could
result
tissu
injuri
acut
rather
chronic
set
thu
although
sever
possibl
rais
involv
transfus
wbc
rbc
mechan
ie
either
nonwbcreduc
wbcreduc
abt
might
associ
increas
mortal
event
relationship
confirm
futur
rctsi
unknown
rct
van
de
water
et
al
design
investig
associ
nonwbcreduc
abt
postop
infectionfound
instead
associ
associ
nonwbcreduc
abt
mortal
caus
fig
associ
abt
mortal
report
dataderiv
hypothesi
author
postul
nonwbcreduc
abt
may
predispos
mof
mightin
turnpredispos
mortal
investig
undertook
anoth
rct
confirm
associ
abt
shortterm
mortal
find
associ
nonwbcreduc
abt
increas
mof
late
unit
kingdom
canada
sever
countri
implement
univers
wbc
reduct
cellular
blood
compon
mean
prestorag
filtrat
permit
comparison
mortal
recipi
nonwbcreduc
rbc
implement
wbc
reduct
mortal
recipi
wbcreduc
rbc
implement
wbc
reduct
et
al
observ
author
enrol
patient
arm
receiv
prestoragefilt
wbcreduc
poststoragefilt
wbcreduc
nonwbcreduc
rbc
wbcreduc
arm
produc
ident
result
combin
one
arm
find
regard
studi
primari
outcom
postop
infect
signific
differ
secondari
outcom
mortal
attain
signific
comparison
absolut
risk
differ
mortal
would
indic
everi
transfus
cardiac
surgeri
patient
might
die
receipt
nonwbcreduc
oppos
wbcreduc
rbc
platelet
administ
patient
enrol
trial
wbc
reduc
transfusionrel
mortal
signific
p
decreas
shortterm
mortal
wbc
reduct
introduc
offer
hypothesi
observ
decreas
number
death
might
due
proinflammatori
microvascular
effect
transfus
wbc
affect
sever
organ
system
hypothesi
buttress
find
companion
studi
prematur
infant
set
implement
univers
wbc
reduct
coincid
reduct
sever
secondari
morbid
outcom
sever
organ
system
ie
bronchopulmonari
dysplasia
retinopathi
prematur
necrot
enterocol
observ
consist
diffus
proinflammatori
microvascular
effect
allogen
wbc
product
contrast
observ
howev
metaanalysi
avail
studi
found
neither
unadjust
adjust
associ
wbc
reduct
decreas
shortterm
mortal
eleven
rct
compar
recipi
nonwbcreduc
vs
wbcreduc
allogen
rbc
present
inform
shortterm
month
posttransfus
mortal
caus
across
rct
conduct
cardiac
surgeri
transfus
rbc
filter
storag
nonwbcreduc
arm
nonwbcreduc
vs
wbcreduc
abt
associ
increas
postop
mortal
summari
ci
p
b
contrast
across
rct
conduct
set
nonwbcreduc
vs
wbcreduc
abt
associ
increas
postop
mortal
advers
effect
seen
across
open
heart
surgeri
studi
may
associ
factor
preval
set
patient
undergo
cardiac
surgeri
cardiac
surgeri
exposur
extracorpor
circuit
hypothermia
reperfus
injuri
may
gener
sir
counteract
compensatori
antiinflammatori
respons
syndrom
intervent
biolog
respons
modifi
eg
solubl
mediat
contain
store
nonwbcreduc
rbc
alreadi
exist
inflammatori
cascad
could
thu
produc
imbal
sirscompensatori
antiinflammatori
respons
syndrom
equilibrium
toward
sir
overwhelm
sir
caus
dormant
state
cell
metabol
refer
mod
ultim
lead
mof
death
howev
associ
nonwbcreduc
vs
wbcreduc
abt
mof
report
rct
mechan
nonwbcreduc
vs
wbcreduc
abt
associ
increas
mortal
cardiac
surgeri
remain
unknown
complet
rct
nonwbcreduc
vs
wbcreduc
abt
associ
particular
caus
death
yet
aggreg
mortal
higher
nonwbcreduc
vs
wbcreduc
arm
review
variou
caus
transfusionrel
mortal
unit
state
today
author
priorit
strategi
feel
institut
reduc
transfusionrel
mortal
priorit
summar
tabl
reflect
opinion
greatli
influenc
fact
thatalthough
risk
new
poorli
understood
infecti
diseas
long
incub
period
transmit
abt
accumul
blood
donor
popul
clinic
consequ
becom
appar
remain
greatest
possibl
threat
blood
safetyto
extent
awar
hivlik
emerg
pathogen
current
appear
horizon
reason
pathogen
reduct
pr
technolog
platelet
plasma
current
licens
augment
patient
identif
procedur
addit
inform
technolog
ii
prevent
addit
rbc
alloantibodi
format
patient
like
need
multipl
transfus
futur
avoid
pool
blood
product
pool
whole
bloodderiv
platelet
white
blood
cell
reduct
cellular
blood
compon
administ
periop
cardiac
surgeri
pathogen
reduct
platelet
plasma
compon
priorit
accord
impact
upon
reduc
number
abtrel
death
highest
lowest
impact
strategi
priorit
reflect
author
opinion
unit
state
priorit
pr
last
among
propos
strategi
regard
hierarchi
strategi
would
chang
dramat
major
transfusiontransmit
pathogen
emerg
although
top
strategi
avoid
abt
evidencebas
transfus
guidelin
would
like
remain
top
list
transfus
blood
bleed
patient
rest
solid
principl
resuscit
tissu
oxygen
replet
vital
element
hemostasi
mani
live
save
abt
given
bleed
patient
mani
case
abt
serv
exquisit
lifesupport
measur
intervent
use
stop
hemorrhag
contrast
abt
given
prophylaxi
abnorm
screen
test
result
coagul
associ
unfavor
risktobenefit
ratio
unnecessari
abt
avoid
use
transfus
guidelin
potenti
tantamount
avoid
one
sever
infecti
noninfecti
caus
abtrel
mortal
discuss
includ
death
attribut
abt
observ
studi
rct
pathophysiolog
mechan
yet
understand
probabl
prevent
strategi
use
abt
per
se
rather
allogen
wbc
solubl
wbcderiv
mediat
accumul
supernat
fluid
rbc
storag
inde
relat
allcaus
mortal
illdefin
mechan
associ
abt
oppos
nonwbcreduc
vs
wbcreduc
abt
mortal
confirm
abt
would
emerg
consider
riski
medic
intervent
thu
evidencebas
transfus
guidelin
prevent
unnecessari
transfus
could
save
live
combin
safeti
measur
discuss
review
even
associ
confirm
futur
rct
use
evidencebas
transfus
guidelin
transfus
blood
compon
rbc
platelet
ffp
cryoprecipit
strategi
reduc
risk
ofand
associ
mortal
fromal
current
establish
abt
complic
fig
transfus
blood
compon
never
undergon
prospect
random
test
manner
new
drug
would
expect
undergo
although
rule
transfus
patient
hemoglobin
level
fall
g
dl
less
hematocrit
fall
less
quasireligi
belief
decad
tricc
rct
document
fallaci
previou
faithbas
indoctrin
deliveri
oxygen
use
tissu
partli
understood
theori
rbc
transfus
improv
tissu
oxygen
deliveri
although
alway
clear
potenti
increas
oxygen
deliveri
translat
increas
local
avail
oxygen
tissu
level
increas
intracellular
consumpt
oxygen
microcirculatori
bed
respond
equal
abt
basic
clinic
question
still
warrant
studi
includ
follow
decid
patient
need
rbc
transfus
variabl
assess
identifi
patient
might
benefit
abt
outcom
patient
receiv
one
mani
rbc
transfus
determin
rbc
transfus
effect
low
hemoglobin
level
detriment
critic
ill
patient
higher
hemoglobin
level
could
achiev
without
risk
would
benefit
critic
ill
patient
thu
consider
interest
formul
evidencebas
transfus
guidelin
nonbleed
patient
recent
septemb
stateofthesci
symposium
transfus
medicin
hemostasi
held
nation
heart
lung
blood
institut
nation
institut
health
bethesda
md
present
concept
propos
rct
transfus
medicin
pertain
formul
appropri
indic
transfus
variou
blood
compon
aim
develop
criteria
appropri
transfus
rbc
develop
criteria
appropri
transfus
platelet
develop
criteria
appropri
transfus
ffp
importantli
concept
propos
propos
investig
safeti
lower
transfus
trigger
safeti
withhold
prophylact
transfus
platelet
ffp
wherea
present
propos
investig
possibl
benefit
obtain
higher
transfus
trigger
evid
appropri
indic
transfus
rbc
clinic
stabl
adult
neonat
patient
produc
rct
conduct
north
america
evid
also
avail
prophylact
platelet
transfus
given
hematooncolog
patient
hypoprolif
thrombocytopenia
hitherto
becom
avail
prophylact
platelet
ffp
transfus
administ
set
red
blood
cell
transfus
trigger
stabl
adult
patient
tricc
rct
although
differ
attain
signific
comparison
primari
mortal
outcom
p
alloc
liber
rather
restrict
transfus
strategi
armwhich
result
averag
transfus
rbc
unit
icuwa
margin
associ
increas
absolut
risk
death
hospit
p
find
confirm
anoth
rct
interim
attribut
effect
multipl
comparison
report
sever
mortal
morbid
outcom
author
tricc
rct
fig
confirm
futur
rct
would
suggest
everi
patient
receiv
abt
per
liber
criteria
hemoglobin
level
fall
gdl
less
oppos
fall
gdl
less
patient
might
die
herhi
hospit
excess
rbc
transfus
receiv
fig
although
figur
far
establish
would
repres
stagger
number
death
secondari
abt
even
order
magnitud
rct
clearli
need
produc
unambigu
signific
p
b
result
respect
differ
primari
mortal
outcom
well
determin
whether
find
tricc
rct
pertain
clinic
set
outsid
icu
howev
base
exist
find
physician
endeavor
limit
patient
exposur
abt
administ
rbc
transfus
rais
hemoglobin
level
patient
hemoglobin
level
fall
gdl
less
provid
patient
activ
bleed
ischem
heart
diseas
hemoglobin
level
g
dl
mainten
hemoglobin
level
g
dl
tricc
rct
reach
abt
rbc
transfus
withheld
unless
patient
symptom
sign
relat
anemia
tricc
rct
unambigu
demonstr
transfus
hemoglobin
target
level
less
gdl
good
transfus
hemoglobin
target
level
less
gdl
mainten
hemoglobin
level
gdl
absenc
symptom
sign
anemia
fig
analysi
patient
statist
signific
p
b
differ
arm
adjust
mod
differ
baselin
score
well
develop
myocardi
infarct
pulmonari
edema
signific
differ
favor
restrict
strategi
arm
moreov
sole
except
septic
shock
fig
observ
trend
favor
restrict
strategi
arm
well
compar
liber
strategi
arm
patient
restrict
strategi
arm
consist
demonstr
better
clinic
outcom
mortal
mof
length
stay
hospit
icu
organspecif
complic
studi
complic
admittedli
tricc
rct
left
open
possibl
trial
arm
might
wors
outcom
would
case
third
standardofcar
arm
also
includ
arm
physician
would
allow
use
judgment
transfus
hemoglobin
target
level
less
gdl
less
gdl
base
assess
patient
clinic
present
possibl
remain
examin
futur
rct
includ
recent
complet
function
outcom
cardiovascular
patient
undergo
surgic
hip
fractur
repair
focu
transfus
trigger
trial
pilot
studi
focu
rct
show
differ
mortal
liber
restrict
transfus
strategi
arm
except
tricc
rct
pilot
focu
trial
rct
evalu
rbc
transfus
trigger
adult
patient
therefor
time
write
clinic
stabl
adult
patient
evid
rct
liber
transfus
strategi
administr
blood
transfus
hemoglobin
level
fall
lower
target
valu
gdl
confer
benefit
patient
compar
restrict
transfus
strategi
administr
rbc
transfus
hemoglobin
level
reach
gdl
fall
lower
target
contrast
overal
result
tricc
rct
show
trend
toward
reduc
mortal
patient
random
restrict
strategi
arm
subgroup
analysi
patient
ischem
heart
diseas
show
trend
toward
reduc
mortal
liber
strategi
arm
reason
focu
rct
enrol
patient
determin
whether
subject
cardiovascular
diseas
cardiovascular
risk
factor
undergo
surgic
repair
hip
fractur
benefit
higher
gdl
vs
lower
gdl
transfus
trigger
find
focu
final
present
hope
end
debat
whether
recommend
use
rbc
transfus
maintain
hemoglobin
level
greater
gdl
highrisk
patient
adher
rational
transfus
patient
impair
ventricular
function
hemoglobin
level
gdl
lack
compensatori
increas
cardiac
output
leav
abt
mean
increas
oxygen
deliveri
postop
red
blood
cell
transfus
trigger
stabl
low
birth
weight
neonat
benefit
liber
vs
restrict
transfus
strategi
vs
clinic
equival
also
remain
elucid
low
birth
weight
preterm
infant
canadian
prematur
infant
need
transfus
rct
enrol
neonat
birth
weight
less
kg
record
composit
outcom
restrict
strategi
arm
vs
liber
strategi
arm
p
composit
outcom
consist
death
discharg
hospit
surviv
sever
retinopathi
bronchopulmonari
dysplasia
andor
brain
injuri
cranial
ultrasound
owe
multipl
exclus
criteria
neonat
enrol
prematur
infant
need
transfus
trial
may
betterthanaverag
prognosi
recent
infant
neurodevelopment
outcom
assess
month
age
statist
differ
primari
outcom
death
presenc
cerebr
palsi
cognit
delay
sever
visual
hear
impair
found
infant
restrict
arm
infant
liber
arm
also
differ
preplan
secondari
outcom
howev
differ
cognit
delay
mental
develop
index
score
approach
statist
signific
post
hoc
analysi
mental
develop
index
score
redefin
show
statist
signific
differ
favor
liber
strategi
arm
small
us
rct
enrol
infant
birth
weight
kg
conclud
infant
restrict
strategi
arm
like
intraparenchym
brain
hemorrhag
periventricular
leukomalacia
also
frequent
episod
mild
sever
apnea
conclus
howev
base
small
number
event
vs
vs
infant
respect
grade
iv
brain
hemorrhag
grade
iv
brain
hemorrhag
andor
periventricular
leukomalacia
benefit
liber
transfus
strategi
need
investig
futur
rct
prophylact
platelet
dose
hematooncolog
patient
prophylact
platelet
dose
transfus
outcom
plado
rct
conclud
safe
transfus
platelet
prophylact
hematooncolog
patient
hypoprolif
thrombocytopeniawhen
trigger
reachedat
dose
half
customari
dose
data
analyz
patient
hospit
trial
site
receiv
least
platelet
transfus
patient
transfus
prophylact
monitor
platelet
count
less
differ
transfus
trigger
dose
therapeut
indic
whether
end
point
bleed
world
health
organ
grade
greater
bleed
greater
grade
proport
patient
develop
bleed
whether
assign
receiv
half
standard
dose
standard
dose
twice
standard
dose
respect
plateletsm
plateletsm
plateletsm
correspond
half
singledonor
concentr
one
singledonor
concentr
singledonor
concentr
equival
dose
pool
whole
bloodderiv
platelet
common
bleed
site
gastrointestin
tract
genitourinari
tract
differ
bleed
site
among
arm
except
oral
bleed
common
halfthestandarddos
arm
compar
standarddos
twicethestandarddos
arm
regardless
random
transfusionrel
mortal
arm
subject
monitor
platelet
count
less
highest
bleed
risk
equival
bleed
risk
observ
platelet
count
also
differ
arm
number
rbc
unit
transfus
grade
bleed
includ
gross
bleed
hematuria
hematemesi
other
grade
bleed
requir
rbc
transfus
grade
bleed
lifeor
organthreaten
median
number
day
greater
grade
bleed
arm
patient
stratifi
caus
hypoprolif
thrombocytopenia
chemotherapi
hematolog
malign
solid
tumor
vs
autolog
allogen
bone
marrow
transplant
platelet
dose
affect
bleed
patient
stratum
patient
receiv
half
standard
dose
transfus
episod
patient
arm
episod
respect
p
b
also
transfus
lower
total
number
platelet
median
respect
although
differ
total
transfus
dose
platelet
receiv
halfthestandarddos
vs
standarddos
arm
small
statist
signific
p
base
find
plado
rct
rct
design
investig
whether
might
safe
altogeth
abandon
practic
prophylact
platelet
transfus
hematooncolog
patient
less
instead
transfus
platelet
therapeut
patient
clinic
bleed
suffici
requir
intervent
nonetheless
strategi
transfus
platelet
rct
similarli
compar
lowdos
standarddos
prophylact
platelet
transfusionswa
termin
earli
data
safeti
monitor
board
differ
prespecifi
stop
rule
trial
grade
bleed
reach
time
patient
lowdos
arm
vs
patient
standarddos
arm
grade
bleed
proport
patient
lowdos
arm
vs
standarddos
arm
experienc
grade
greater
bleed
howev
differ
number
donor
exposur
arm
mean
sd
lowdos
vs
standarddos
arm
p
mean
interv
transfus
day
respect
vs
neither
plado
strategi
transfus
platelet
rct
use
exclus
singledonor
apheresi
platelet
lowdos
arm
clinic
set
need
platelet
transfus
everi
day
howev
possibl
devis
inventori
manag
practic
wherebi
second
half
singledonor
platelet
concentr
administ
patient
subject
inpati
requir
second
platelet
transfus
within
shelf
life
product
accord
mani
clinician
outpati
might
better
receiv
standard
dose
maxim
interv
platelet
transfus
manner
reli
exclus
split
apheresi
platelet
concentr
reduct
total
number
transfus
platelet
p
demonstr
plado
rct
could
translat
clinic
signific
reduct
number
donor
exposur
hematooncolog
patient
support
prophylact
platelet
transfus
half
dose
current
regard
standard
prophylact
platelet
ffp
transfus
extens
bodi
evid
observ
studi
indic
patient
moder
decreas
platelet
count
moder
elev
intern
normal
ratio
inr
underw
varieti
invas
procedur
central
venou
cathet
insert
liver
biopsi
thoracocentesi
paracentesi
gastrointestin
endoscopi
biopsi
tracheotomi
bronchoscopi
transbronchi
biopsi
renal
biopsi
diagnost
lumbar
punctur
epidur
anesthesia
neurolog
procedur
angiographi
without
receiv
transfus
platelet
ffp
bleed
often
patient
receiv
prophylact
platelet
ffp
transfus
procedur
absenc
coagulopathi
avail
observ
studi
suggest
platelet
count
greater
adequ
perform
procedur
without
prophylact
platelet
transfus
convers
platelet
count
greater
avail
observ
studi
suggest
inr
less
adequ
perform
procedur
without
need
prophylact
plasma
transfus
data
rct
howev
support
safeti
conserv
transfus
vamvaka
blajchman
trigger
thu
liber
transfus
guidelin
prophylact
platelet
ffp
transfus
use
mani
us
institut
accord
avail
publish
transfus
guidelin
safeti
trigger
platelet
absenc
coagulopathi
inr
platelet
count
unlik
demonstr
rct
forese
futur
rct
use
clinic
bleed
primari
end
point
would
enrol
prohibit
larg
number
patient
establish
differ
arm
small
proport
subject
either
conserv
liber
strategi
transfus
arm
expect
bleed
colleg
american
pathologist
guidelin
recommend
transfus
ffp
coagul
time
greater
time
midpoint
normal
rang
laboratori
perform
test
canadian
medic
associ
guidelin
state
plasma
may
administ
prepar
surgeri
liver
biopsi
result
coagul
assay
deem
suffici
abnorm
prophylact
plasma
transfus
indic
certain
invas
procedur
eg
percutan
liver
biopsi
paracentesi
thoracentesi
patient
liver
diseas
inr
less
review
data
observ
studi
procedur
perform
patient
platelet
count
less
less
even
less
without
prophylact
platelet
transfus
american
societi
clinic
oncologist
panel
conclud
platelet
count
suffic
perform
lumbar
punctur
liver
biopsi
gastrointestin
endoscopi
fiberopt
bronchoscopi
bronchoalveolar
lavag
transbronchi
biopsi
central
venou
cathet
insert
tooth
extract
panel
observ
spars
data
safeti
invas
procedur
much
lower
count
level
howev
except
bone
marrow
aspir
biopsi
clearli
perform
safe
count
panel
stop
short
make
recommend
difficult
draw
firm
datadriven
conclus
lower
level
platelet
count
safe
variou
procedur
panel
accordingli
conclud
systemat
research
area
clearli
need
british
committe
standard
hematolog
guidelin
use
platelet
ffp
massiv
transfus
anticip
coagul
time
greater
time
mean
normal
valu
replac
time
patient
blood
volum
platelet
count
less
replac
time
patient
blood
volum
accord
british
committe
standard
hematolog
guidelin
transfus
ffp
platelet
indic
trigger
reach
guidelin
howev
recommend
margin
safeti
allow
ensur
platelet
count
remain
less
toward
end
platelet
transfus
trigger
less
recommend
patient
ongo
bleed
trigger
increas
less
patient
multipl
central
nervou
system
trauma
even
prophylact
set
platelet
transfus
trigger
less
recommend
lumbar
punctur
epidur
anesthesia
gastroscopi
biopsi
insert
indwel
line
transbronchi
biopsi
liver
biopsi
laparatomi
similar
procedur
oper
critic
sitessuch
brain
eyesth
platelet
transfus
trigger
set
less
nonetheless
bone
marrow
aspir
biopsi
perform
even
patient
sever
thrombocytopenia
without
platelet
transfus
support
us
transfus
guidelin
plasma
base
systemat
review
avail
clinic
studi
expect
aabb
near
futur
current
singledonor
pool
whole
bloodderiv
plateletswhich
collect
without
regard
donor
sex
presenc
wbc
antibodi
donorar
probabl
associ
approxim
equal
risk
trali
although
whole
bloodderiv
concentr
contain
time
less
plasma
individu
donor
may
femal
multipar
donor
wbc
antibodi
match
recipi
antigen
recipi
platelet
pool
time
greater
risk
receiv
concentr
femal
multipar
donor
wbc
antibodi
match
recipi
antigen
ml
donor
plasma
suffici
caus
trali
transfus
patient
transfusionrel
mortal
consid
higher
probabl
exposur
ml
plasma
donor
probabl
carri
much
risk
averag
receipt
time
much
plasma
individu
donor
singledonor
platelet
may
similarli
antibodi
match
recipi
antigen
also
avail
limit
data
compar
risk
trali
pool
whole
bloodderiv
vs
singledonor
platelet
tabl
indic
differ
risk
type
compon
importantli
empir
evid
adduc
support
opposit
opinion
compar
pool
whole
bloodderiv
platelet
singledonor
platelet
carri
greater
risk
trali
latter
view
continu
repres
theoret
predict
made
base
antibodi
hypothesi
trali
pathogenesi
predict
continu
carri
forward
base
case
report
small
case
seri
control
studi
data
observ
oppos
passiv
surveil
studiesdirectli
compar
consecut
recipi
singledonor
vs
pool
whole
bloodderiv
platelet
settingar
need
calcul
rel
risk
trali
singledonor
vs
pool
wholebloodderiv
platelet
absenc
report
activ
surveil
studi
conduct
sentinel
site
transfus
singledonor
pool
wholebloodderiv
platelet
inform
data
report
howev
imposs
reach
definit
conclus
rel
risk
trali
associ
singledonor
vs
pool
whole
bloodderiv
platelet
avail
conflict
databas
current
singledonor
pool
whole
bloodderiv
platelet
associ
approxim
equal
risk
trali
tabl
singledonor
platelet
futur
collect
sole
male
donor
femal
donor
without
histori
pregnanc
shown
wbc
antibodi
futur
singledonor
platelet
associ
lower
risk
trali
current
pool
whole
bloodderiv
platelet
mathemat
model
consid
trali
risk
associ
futur
singledonor
platelet
collect
male
donor
appropri
screen
femal
donor
would
lower
risk
trali
associ
current
singledonor
pool
whole
bloodderiv
platelet
trali
lead
caus
transfusionrel
mortal
unit
state
today
fig
move
allapheresi
platelet
suppli
would
reli
exclus
male
donor
femal
donor
without
histori
pregnanc
shown
wbc
antibodi
would
major
improv
transfus
safeti
replic
extent
success
stori
presum
realiz
convers
maleonli
ffp
fig
recent
estim
exclus
femal
donor
circul
wbc
antibodi
would
result
loss
current
us
plateletpheresi
donor
thu
possibl
donor
recruit
effort
replac
small
percentag
current
plateletpheresi
donor
attract
addit
plateletpheresi
donor
harvest
therapeut
platelet
dose
continu
provid
pool
whole
bloodderiv
platelet
unit
state
addit
reduc
risk
trali
allapheresi
platelet
suppli
effect
signific
reduct
risk
tti
ta
tabl
yet
effect
unit
state
pr
platelet
combin
effect
allapheresi
platelet
suppli
lead
caus
transfusionrel
mortal
unit
state
today
trali
ta
well
reduct
risk
hivlik
wnvlike
agent
emerg
futur
believ
allapheresi
platelet
suppli
reli
exclus
male
donor
femal
donor
without
histori
pregnanc
femal
donor
shown
wbc
antibodi
may
second
conserv
transfus
guidelin
impact
upon
reduc
transfusionrel
mortal
unit
state
today
although
recommend
allapheresi
platelet
suppli
base
sole
safeti
concurr
possibl
benefit
hitherto
well
document
literatur
may
increas
efficaci
singledonor
compar
pool
whole
bloodderiv
platelet
treat
patient
thrombocytopenia
studi
radiolabel
autolog
platelet
done
volunt
show
platelet
recoveri
surviv
significantli
better
singledonor
compar
whole
bloodderiv
platelet
also
metaanalysi
rct
show
correct
count
increment
significantli
higher
singledonor
compar
pool
whole
bloodderiv
platelet
transfus
patient
leukemia
receiv
prophylact
platelet
transfus
first
day
stemcel
transplant
singledonor
compar
pool
whole
bloodderiv
platelet
produc
better
correct
count
increment
although
compon
equal
effect
prevent
hemorrhag
small
studi
augment
patient
identif
procedur
continu
occurr
fatal
abo
htr
fig
abt
hazard
whose
root
caus
virtual
alway
human
error
logist
problem
tri
solv
sinc
deplor
inexcus
hard
understand
implement
inform
technolog
would
supplement
rather
replac
proper
patient
identif
procedur
time
collect
pretransfus
sampl
andeven
importantat
time
transfus
donor
unit
recipi
yet
mandat
us
regulatori
agenc
fda
joint
commiss
accredit
hospit
four
decad
fatal
secondari
abo
htr
demonstr
reli
sole
medic
profession
prevent
hazard
alway
follow
proper
procedur
inadequ
indepth
train
transfusionist
strict
adher
proper
procedur
supplement
robust
inform
technolog
prevent
addit
rbc
alloantibodi
format
fatal
nonabo
htr
fig
may
requir
farreach
chang
blood
bank
practic
prevent
appropri
chang
continu
debat
data
shonewil
et
al
would
argu
introduct
extend
antigen
match
prevent
format
addit
rbc
alloantibodi
patient
alreadi
form
first
rbc
alloantibodi
probabl
form
addit
rbc
antibodi
rbc
transfus
transfusionrel
mortal
patient
format
addit
alloantibodi
associ
complex
serolog
workup
delay
provis
compat
blood
well
delay
acut
htr
prevent
format
addit
rbc
alloantibodi
would
signific
move
toward
optim
transfus
safeti
accord
shonewil
et
al
extend
antigen
match
donor
recipi
restrict
antigen
highest
immun
risk
ie
c
c
e
k
fy
jk
find
compat
blood
donor
would
routin
feasibl
netherland
find
compat
donor
would
problemat
howev
extend
match
donor
recipi
also
includ
jk
b
antigen
although
debat
extens
extend
antigen
match
donor
recipi
ought
whether
offer
transfus
recipi
made
first
rbc
alloantibodi
reserv
select
categori
alloimmun
patient
believ
time
come
principl
extend
antigen
match
donor
recipi
note
assum
peak
epidem
measur
introduc
interrupt
transmiss
abt
next
hivlik
pathogen
emerg
futur
reach
preval
per
donat
popul
elig
us
blood
donor
accord
whitak
et
al
median
number
whole
bloodderiv
platelet
concentr
per
platelet
pool
observ
us
hospit
base
publish
mathemat
model
residu
risk
transmiss
hiv
hcv
hbv
window
period
infect
best
case
scenario
indic
smaller
rel
risk
transmiss
pathogen
transfus
pool
whole
bloodderiv
vs
singledonor
platelet
one
singledonor
concentr
equival
whole
bloodderiv
platelet
concentr
signific
proport
greater
singledonor
concentr
repres
split
product
infect
plateletpheresi
donor
infect
occasion
even
rather
recipi
infect
plateletpheresi
donor
donat
window
period
least
tti
eg
hbv
infect
worst
case
scenario
indic
greater
rel
risk
transmiss
pathogen
transfus
pool
whole
bloodderiv
vs
singledonor
platelet
one
singledonor
concentr
observ
equival
pool
whole
bloodderiv
concentr
actual
us
practic
whitak
et
al
rang
median
higher
proport
plateletpheresi
compar
wholeblood
donor
repeat
donor
therebi
presum
lower
risk
incid
hiv
hcv
hbv
infect
patient
receiv
pool
whole
bloodderiv
platelet
concentr
may
receiv
transfus
second
pool
well
inadequ
correct
count
increment
dose
escal
usual
approach
nonimmun
caus
platelet
refractori
recipi
either
pool
whole
bloodderiv
singledonor
platelet
may
receiv
second
even
third
therapeut
platelet
dose
well
latter
case
pool
whole
bloodderiv
platelet
would
expos
recipi
consider
donor
singledonor
concentr
thu
best
worst
case
scenario
deem
repres
extrem
plausibl
rang
annual
number
case
tti
could
prevent
therapeut
platelet
dose
unit
state
provid
singledonor
concentr
assum
pool
whole
bloodderiv
platelet
distribut
unit
state
soon
prepool
cultur
fig
reproduc
wnv
experi
summer
fall
calcul
assum
infect
would
contract
abt
blood
compon
made
whole
blood
equal
infecti
wide
endors
implement
minimum
extend
antigen
match
includ
c
e
k
antigen
well
extend
hematooncolog
patient
addit
patient
hemoglobinopathi
preval
rbc
alloantibodi
hematooncolog
patient
rang
patient
chanc
form
addit
rbc
alloantibodi
form
first
antibodi
believ
alreadi
alloimmun
hematooncolog
patient
offer
standard
care
patient
sickl
cell
diseas
preval
alloimmun
rang
blood
bank
use
genotyp
rather
phenotyp
donor
recipi
well
electron
inventori
manag
system
extend
antigen
match
two
possibl
expand
extend
match
beyond
c
e
k
antigen
beyond
hematooncolog
patient
patient
hemoglobinopathi
without
insurmount
rise
workload
clearli
avoid
rbc
alloimmun
benefit
patient
technolog
rapidli
advanc
support
extend
donor
genotyp
repositori
routin
extend
antigen
match
donor
recipi
counterargu
relat
magnitud
expect
benefit
consequ
costbenefit
ratio
associ
genotyp
technolog
vs
technolog
discuss
review
well
other
necessari
function
present
vy
resourc
patient
sickl
cell
diseas
higher
standard
care
justifi
inflammatori
respons
associ
transfus
reaction
provok
sickl
cell
crisi
stroke
sever
complic
consider
benefit
appli
alloimmun
hematooncolog
patient
alloimmun
transfus
recipi
extend
antigen
match
intend
prevent
morbid
mortal
associ
acut
delay
htr
yet
although
death
delay
htr
exceedingli
rare
passiv
report
death
nonabo
htr
shown
figur
make
extend
antigen
match
donor
recipi
safeti
measur
worthi
implement
absenc
pr
base
past
experi
hiv
hcv
hivlik
pathogen
could
emerg
futur
remain
greatest
threat
blood
safeti
moreov
even
pr
method
develop
could
protect
blood
suppli
emerg
agent
priorit
aabb
task
forc
exampl
agent
list
report
patholog
prion
human
parvoviru
hepat
viru
would
inactiv
would
probabl
inadequ
inactiv
pr
also
born
mind
concept
emerg
infect
evolut
manifest
well
properti
associ
pathogen
intrins
unpredict
pr
procedur
almost
alway
valid
transfusiontransmit
agent
alreadi
known
thu
emerg
infect
may
neither
inactiv
pr
associ
specif
highrisk
group
whose
deferr
blood
donat
could
prevent
transmiss
transfus
recipi
latter
would
case
next
major
transfusiontransmit
pathogen
emerg
foodborn
vcjd
vectorborn
wnv
even
airborn
sever
acut
respiratori
syndrom
therefor
reduc
number
donor
patient
expos
strategi
reduc
risk
transmiss
tti
might
emerg
futur
success
strategi
depend
prevent
unnecessari
transfus
enforc
evidencebas
transfus
guidelin
hospit
side
lot
accomplish
blood
center
side
well
avoid
distribut
pool
blood
product
especi
pool
whole
bloodderiv
platelet
provid
therapeut
benefit
recipi
could
obtain
transfus
singledonor
platelet
concentr
pool
whole
bloodderiv
platelet
expos
patient
time
mani
donor
apheresi
product
tabl
show
number
case
tti
could
prevent
annual
unit
state
unit
state
provid
therapeut
platelet
dose
transfus
patient
form
singledonor
concentr
despit
figur
debat
unit
state
whether
appropri
transfusionrel
mortal
revert
provid
prepool
cultur
whole
bloodderiv
platelet
altern
provid
singledonor
platelet
collect
exclus
male
donor
femal
donor
without
histori
pregnanc
femal
donor
shown
wbc
antibodi
base
aabb
recommend
trali
prevent
histor
singledonor
platelet
consid
mani
associ
higher
risk
trali
compar
pool
whole
bloodderiv
platelet
contain
time
much
plasma
singl
donor
potenti
collect
femal
donor
previous
pregnant
circul
wbc
antibodi
direct
recipi
antigen
yet
albeit
report
trali
associ
pool
whole
bloodderiv
platelet
trali
document
occur
associ
transfus
blood
compon
contain
littl
ml
plasma
higher
risk
trali
associ
singledonor
compar
pool
whole
bloodderiv
platelet
document
observ
studi
rct
compar
type
platelet
compon
set
type
platelet
concentr
transfus
patient
popul
condit
time
recent
systemat
review
literatur
retriev
studi
diagnos
trali
base
canadian
consensu
criteria
real
time
set
transfus
singledonor
pool
whole
bloodderiv
plateletsand
report
risk
trali
separ
singledonor
platelet
vs
either
whole
bloodderiv
platelet
platelet
pool
tabl
summar
attribut
find
studi
includ
systemat
review
studi
observ
risk
trali
approxim
equal
per
singledonor
concentr
per
pool
whole
bloodderiv
platelet
absenc
recent
trali
death
attribut
pool
whole
bloodderiv
platelet
report
passiv
fda
fig
featur
debat
whether
unit
state
increas
relianc
prepool
cultur
whole
bloodderiv
vs
singledonor
platelet
observ
reason
therapeut
platelet
dose
continu
provid
pool
whole
bloodderiv
platelet
unit
state
trali
fatal
ascrib
pool
whole
bloodderiv
platelet
passiv
report
fda
transfus
platelet
pool
inde
associ
risk
fatal
trali
altern
absenc
fatal
may
due
chanc
report
death
repres
exceedingli
rare
event
yet
anoth
explan
could
lack
trali
awar
recognit
environ
pool
whole
bloodderiv
platelet
administeredcertainli
possibl
trali
known
grossli
underrecogn
underreport
similarli
trali
periodwhen
pool
whole
bloodderiv
platelet
subject
bacteri
cultur
screen
bacteria
surrog
method
time
less
sensit
cultur
fatal
ta
ascrib
transfus
pool
whole
bloodderiv
platelet
report
us
fda
fig
period
fatal
ta
attribut
transfus
singledonor
platelet
continu
report
fig
despit
fact
latter
compon
cultur
bacteria
absenc
report
death
ta
trali
associ
transfus
pool
whole
bloodderiv
platelet
subject
cultur
support
hypothesi
pool
whole
bloodderiv
platelet
unit
state
like
administ
environ
less
monitor
transfus
reaction
less
access
transfus
medicin
expertis
case
differ
number
passiv
report
death
associ
type
platelet
compon
ascrib
passiv
surveil
artifact
describ
section
sourc
data
interpret
context
passiv
surveil
artifact
cloud
interpret
data
passiv
submit
fda
may
oper
yet
anoth
manner
public
associ
trali
risk
transfus
ffp
may
led
increas
awar
risk
trali
associ
withspecificallyffp
transfus
fig
oppos
transfus
blood
compon
includ
type
platelet
compon
ffp
problem
regard
solv
convers
male
fig
number
may
well
rise
greater
part
ta
mortal
may
deriv
establish
noninfecti
infecti
complic
abt
corrobor
futur
research
death
attribut
nonwbcreduc
vs
wbcreduc
abt
rct
conduct
cardiac
surgeri
repres
far
greater
number
death
fatal
caus
mani
wellrecogn
transfus
complic
although
mortal
secondari
outcom
cardiac
surgeri
rct
van
de
water
et
al
receipt
nonwbcreduc
compar
wbcreduc
abt
increas
absolut
risk
death
vs
indic
everi
patient
receiv
nonwbcreduc
rather
wbcreduc
abt
might
die
nonwbcreduc
rather
wbcreduc
abt
allogen
blood
transfus
associ
specif
caus
death
rct
mechan
abt
might
caus
increas
allcaus
mortal
yet
understood
although
need
research
elucid
mechan
appar
increas
mortal
recipi
nonwbcreduc
compar
wbcreduc
abt
believ
thatwher
excess
mortal
attribut
nonwbcreduc
compar
wbcreduc
abt
rctswbc
reduct
cellular
blood
compon
implement
prevent
excess
death
situat
report
cardiac
surgerya
set
apart
surgic
medic
set
idiosyncrat
effect
abt
could
expect
would
necessarili
generaliz
set
approxim
platelet
rbc
unit
current
transfus
unit
state
wbc
reduc
number
wbcreduc
compon
declin
million
compon
us
hospit
use
wbcreduc
compon
either
univers
select
depend
primarili
geograph
locat
practic
local
blood
center
may
manufactur
wbcreduc
wbcreduc
nonwbcreduc
cellular
blood
compon
select
wbc
reduct
use
administr
wbcreduc
compon
cardiac
surgeri
patient
usual
includ
among
establish
indic
wbc
reduct
thu
us
hospit
wbcreduc
rbc
administ
routin
patient
whose
mortal
shown
affect
wbc
reduct
wherea
elsewher
cardiac
surgeri
patient
whose
mortal
shown
improv
wbc
reduct
may
alway
receiv
wbcreduc
compon
ensur
cardiac
surgeri
patient
receiv
wbcreduc
cellular
blood
compon
could
either
redistribut
alreadi
manufactur
wbcreduc
cellular
blood
compon
us
hospit
use
univers
wbc
reduct
cardiac
surgeri
set
us
hospit
use
univers
wbc
reduct
could
increas
overal
proport
cellular
blood
compon
wbcreduc
unit
state
whether
goal
accomplish
redistribut
net
increas
manufactur
wbcreduc
compon
believ
cellular
blood
compon
transfus
cardiac
surgeri
unit
state
wbcreduc
base
exist
evid
us
hospit
use
select
wbc
reduct
safeti
enhanc
accomplish
ad
cardiac
surgeri
establish
indic
wbc
reduct
name
prevent
hla
alloimmun
refractori
randomdonor
platelet
transfus
prevent
transmiss
cmv
prevent
febril
nonhemolyt
transfus
reaction
mani
agent
potenti
threaten
blood
safeti
blood
establish
easili
keep
implement
safeti
measur
respons
one
rather
agentbyag
approach
allencompass
proactiv
approach
blood
safeti
would
address
transfusiontransmit
pathogen
use
pr
nucleic
acid
intercal
agent
ie
psoralen
riboflavin
presenc
ultraviolet
light
technolog
bind
photosensit
agent
nucleic
acid
pathogen
inactiv
permit
nucleic
acidfre
constitu
donor
blood
plasma
protein
platelet
rbc
continu
function
thu
technolog
elimin
residu
risk
bacteria
well
risk
associ
long
list
transfusiontransmit
pathogen
blood
suppli
screen
eg
plasmodium
sp
babesia
sp
perhap
import
technolog
offer
potenti
preemptiv
protect
next
potenti
lethal
transfusiontransmit
agent
inevit
emerg
futur
replic
experi
hiv
wnv
technolog
current
avail
platelet
ffp
accept
safeti
profil
alreadi
licens
use
western
european
countri
although
safeti
improv
confer
wide
acknowledg
debat
whether
pr
platelet
plasma
introduc
suitabl
pr
technolog
also
becom
avail
rbc
contribut
pr
safeti
suboptim
pr
technolog
simultan
also
appli
rbc
latter
continu
transmit
pathogen
transfus
recipi
also
comprehens
system
pr
also
encompass
rbc
permit
variou
costsav
possibl
discontinu
safeti
measur
cost
pr
bound
increment
substanti
howev
mani
patient
receiv
repeat
platelet
transfus
intermitt
accompani
rbc
transfus
andhowev
medic
inappropri
platelet
andor
ffp
transfus
often
given
prophylact
patient
schedul
undergo
bedsid
invas
procedur
moder
lower
platelet
count
moder
elev
inr
pathogen
reduct
like
protect
recipi
futur
transfusiontransmit
pathogen
ineffect
patholog
prion
ie
vcjd
agent
intracellular
pathogen
sporeform
bacteria
nonenvelop
virus
virus
present
exceedingli
high
concentr
blood
anoth
downsid
caus
cellular
function
protein
loss
thu
reduc
therapeut
efficaci
blood
compon
necessit
transfus
greater
volum
blood
expos
patient
donor
therebi
increas
risk
transmiss
agent
inactiv
pr
despit
plausibl
predict
howev
rbc
platelet
use
report
remain
introduct
pathogen
inactiv
system
western
european
countri
also
increas
platelet
transfus
need
patient
receiv
platelet
treat
riboflavinbas
pr
technolog
compar
subject
untreat
arm
one
report
trial
potenti
toxic
effect
candid
pr
system
examin
mani
dimens
vamvaka
blajchman
includ
acut
subacut
chronic
toxic
blood
compon
incompat
genotox
carcinogen
impact
reproduct
develop
although
evid
advers
effect
hitherto
adduc
clinic
event
interest
rare
may
long
latent
period
becom
recogn
especi
regard
mutagen
carcinogen
concern
possibl
longterm
toxic
pr
technolog
allevi
longterm
outcom
report
western
european
countri
pr
technolog
alreadi
least
partli
introduc
clinic
practic
concern
must
consid
howev
context
possibl
addit
shortterm
benefit
pr
technolog
unlik
wbc
reduct
filter
leav
residu
wbc
behind
wbcreduc
blood
compon
pr
technolog
elimin
allogen
wbc
way
prevent
rare
death
tagvhd
occur
patient
given
unirradi
compon
mistak
recogn
indic
irradi
furthermor
rct
efficaci
safeti
platelet
undergon
pr
demonstr
trend
toward
reduc
mortal
patient
support
treat
platelet
concern
especi
mortal
ali
acut
lung
injuri
signific
caus
morbid
mortal
recipi
allogen
bone
marrow
transplantsa
set
ali
may
account
death
pr
truli
render
platelet
less
apt
caus
ali
transfus
recipi
plausibl
explan
effect
would
includ
reduct
cytokin
synthesi
andor
antigen
present
owe
absenc
wbc
treat
product
pathogen
reduct
process
appli
either
singleunit
plasma
unit
plasma
pool
thu
licens
technolog
pr
plasma
europ
clinic
experi
million
u
transfus
hitherto
accru
pool
plasma
subject
solventdeterg
treatment
pool
plasma
donat
disadvantag
one
singl
plasma
unit
contamin
whole
pool
howev
drawback
offset
sever
advantag
includ
virtual
elimin
trali
attribut
wbc
antibodi
signific
reduct
incid
allerg
reaction
owe
dilut
allergen
standard
product
therapeut
use
coagul
factor
content
individu
plasma
donor
contribut
pool
wide
rang
coagul
factor
level
vari
trali
reduct
solventdetergenttr
pool
plasmawhich
current
use
meet
virtual
plasma
need
norway
ireland
contribut
compar
ffp
transfus
unit
plasma
franc
need
compar
maleonli
ffp
current
use
north
america
solventdetergenttr
pool
plasma
effect
maleonli
ffp
reduc
risk
trali
manufactur
process
dilut
possibl
neutral
wbc
antibodi
fact
report
trali
appear
western
european
countri
use
solventdetergenttr
pool
plasma
particular
aforement
period
french
hemovigil
system
start
appropri
monitor
trali
probabl
certain
possibl
case
trali
associ
transfus
ffp
per
u
compar
case
trali
associ
transfus
solventdetergenttr
pool
plasma
furthermor
although
tti
would
occur
associ
use
solventdetergenttr
pool
plasma
singl
contamin
unit
might
contamin
entir
pool
least
theori
situat
pool
offer
advantag
prevent
transmiss
tti
although
data
risk
vcjd
infect
solventdetergenttr
pool
plasma
anyth
low
titer
prion
infect
blood
infect
individu
approxim
infecti
uml
would
greatli
dilut
thousand
unit
plasma
plasma
pool
subsequ
manufactur
process
also
remov
prion
final
product
solventdeterg
treatment
pool
plasma
result
appreci
loss
protein
antitrypsin
antiplasmin
loss
gener
concern
product
use
patient
hyperfibrinolysi
occur
reperfus
stage
liver
transplant
cluster
death
patient
unit
state
solventdetergenttr
pool
plasma
use
fell
favor
north
america
current
manufactur
process
use
europ
differ
result
reducedalbeit
still
appreciableloss
protein
nonetheless
irishwho
almost
exclus
use
solventdetergenttr
pool
plasma
plasma
need
transfus
recipientsdo
use
product
patient
undergo
liver
transplant
predict
next
major
transfusiontransmit
pathogen
emerg
believ
pr
technolog
platelet
plasma
implement
transfus
medicin
commun
licens
rather
wait
pr
technolog
rbc
also
develop
perhap
next
year
next
agent
emerg
envelop
viru
hiv
hbv
hcv
wnv
potenti
futur
hivlik
epidem
fatal
transfusiontransmit
infect
avert
sever
safeti
measur
includ
bacteri
detect
platelet
screen
antibodi
trypanosoma
cruzi
could
also
potenti
discontinu
pr
univers
introduc
blood
product
time
howev
recogn
potenti
debat
pr
neg
effect
safeti
produc
situat
continu
inact
address
residu
risk
bacteria
plateletsta
known
infecti
risk
intervent
discuss
review
four
strategi
propos
evidencebas
transfus
guidelin
avoid
pool
whole
bloodderiv
platelet
avoid
femal
ffp
plateletpheresi
donor
histori
pregnanc
test
neg
wbc
antibodi
well
wbc
reduct
cellular
blood
compon
administ
cardiac
surgeri
alreadi
beenat
least
partlyimpl
unit
state
strategi
alreadi
introduc
howev
adopt
univers
uniformli
benefit
confer
prevent
abtrel
death
yet
fulli
realiz
exampl
therapeut
platelet
dose
continu
provid
pool
whole
bloodderiv
platelet
also
femal
plateletpheresi
donor
histori
pregnanc
test
wbc
antibodi
continu
use
blood
center
debat
approach
handl
donor
rang
test
wbc
antibodi
women
histori
pregnanc
test
women
pregnanc
conclus
allogen
blood
transfus
lifesav
bleed
patient
patient
bleed
requir
posit
evid
benefit
expos
patient
risk
transfus
transfus
never
consid
inher
safe
administ
prophylact
without
evid
efficaci
improv
oxygen
consumpt
tissu
prevent
hemorrhag
although
acknowledg
zero
risk
attain
goal
discuss
recent
progress
blood
safeti
detract
attent
fact
need
done
lessen
sens
urgenc
us
continu
strive
low
reason
achiev
risk
spirit
propos
strategi
risk
reduct
thatwith
except
pr
technolog
plasma
platelet
yet
avail
unit
statesar
opinion
ripe
implement
